eXegenics, Inc.
SCHEDULE 14C
(RULE 14C-101)
INFORMATION REQUIRED IN INFORMATION STATEMENT
SCHEDULE 14C INFORMATION
Information Statement Pursuant to Section 14(c) of the Securities
Exchange Act of 1934 (Amendment No. )
|
|
|
Check the appropriate box: |
|
|
|
o
|
|
Definitive Information Statement |
|
|
|
x
|
|
Preliminary Information Statement |
|
|
|
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) |
EXEGENICS INC.
(Name of Registrant as Specified In Its Charter)
|
|
|
|
|
|
|
Payment of Filing Fee (Check the appropriate box): |
|
|
|
|
|
|
|
x |
|
No fee required. |
|
|
|
|
|
|
|
o |
|
Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. |
|
|
|
|
|
|
|
|
|
|
(1 |
) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2 |
) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3 |
) |
|
Per unit price or other underlying
value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5 |
) |
|
Total fee paid: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
|
|
|
|
|
|
o |
|
Check box if any
part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date of its filing. |
|
|
|
|
|
|
|
|
|
|
(1 |
) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2 |
) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3 |
) |
|
Filing Party: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4 |
) |
|
Date Filed: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
eXegenics
Inc.
D/B/A Opko Health, Inc.
4400 Biscayne Blvd
Suite 900
Miami, Florida 33137
May ,
2007
To the Stockholders of eXegenics Inc.
On May , 2007, eXegenics Inc., a Delaware
corporation doing business as Opko Health, Inc. (the
Company), obtained the written consent of
stockholders holding a majority of the voting power of the
issued and outstanding shares of common stock and preferred
stock of the Company, voting as one class, to approve the
following matters:
|
|
|
|
|
The ratification of the appointment of Ernst & Young
LLP as the Companys independent registered public
accounting firm for 2007.
|
|
|
|
The approval of the Companys 2007 Equity Incentive Plan.
|
|
|
|
The change of the Companys name to Opko Health, Inc..
|
|
|
|
The Amendment and Restatement of the Companys Certificate
of Incorporation to increase the authorized number of common
shares from 225,000,000 to 500,000,000 and to effect the change
of the Companys name to Opko Health, Inc.
|
Such actions will be taken on or about May ,
2007, or approximately twenty (20) days after the mailing
of this Information Statement. In addition, the board of
directors authorized the amendment and restatement of the
Companys Bylaws on April 25, 2007, which does not
require the approval of the Companys stockholders.
This Information Statement will be mailed to you on or about
May , 2007.
No Action is required by you. This Notice and the attached
Information Statement are being circulated to advise the
stockholders of certain actions already approved by written
consent of the stockholders who collectively hold a majority of
the outstanding shares of the Companys common stock and
preferred stock, voting as a single class. Pursuant to
Rule 14c-2
under the Securities Exchange Act of 1934, as amended, the
proposals will not be effective until approximately twenty
(20) days after the date this Information Statement is
mailed to the Companys stockholders. Therefore, this
Notice and the attached Information Statement are being sent to
you for informational purposes only. This Notice and Information
Statement constitutes the notice of corporate action without a
meeting by less than unanimous consent of the Companys
stockholders required by Section 228(e) of the Delaware
General Corporation Law. You are urged to read the Information
Statement carefully in its entirety.
WE ARE
NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND US A PROXY
By Order of the Board of Directors
Phillip Frost, M.D.
Chief Executive Officer
Chairman of the Board
INFORMATION
STATEMENT
PURSUANT TO SECTION 14(C)
OF THE SECURITIES EXCHANGE ACT OF 1934
AND
RULE 14C-2
THEREUNDER
NO VOTE
OR OTHER ACTION OF THE COMPANYS SHAREHOLDERS IS REQUIRED
IN
CONNECTION WITH THIS INFORMATION STATEMENT.
WE ARE
NOT ASKING YOU FOR A PROXY AND
YOU ARE REQUESTED NOT TO SEND US A PROXY
MAY ,
2007
On March 27, 2007, we completed an acquisition of Froptix
Corporation, a privately held Florida corporation, and Acuity
Pharmaceuticals, Inc., a privately held Delaware corporation,
pursuant to a merger agreement and plan of reorganization.
Before the acquisitions, we ceased all operations relating to
our historical business and adopted the business plan of Froptix
and Acuity, each of which is now a wholly-owned subsidiary of
ours.
Following the consummation of the acquisitions, our board of
directors and our stockholders holding a majority of the voting
power of the issued and outstanding shares of common stock and
preferred stock of the Company, voting as one class, approved
the matters set forth in this Information Statement.
References in this Information Statement to Acuity
refer to Acuity Pharmaceuticals, LLC, a wholly owned subsidiary
of ours formerly known as Acuity Pharmaceuticals, Inc.
References in this Information Statement to Froptix
refer to Froptix, LLC, a wholly owned subsidiary of ours
formerly known as Froptix Corporation.
References in this Information Statement to the
Acquisition refers to the acquisitions of Froptix
and Acuity by the Company.
STOCK
OWNERSHIP
The following table sets forth certain information, as of
April 20, 2007, with respect to the beneficial ownership of
our common stock by: (i) each stockholder known by us to be
the beneficial owner of more than 5% of our common stock;
(ii) each director or director nominee; (iii) each
executive officer named in the Summary Compensation Table under
Executive Officers and Executive Compensation in
this Proxy Statement; and (iv) all current executive
officers and directors as a group.
Beneficial ownership is determined in accordance with the rules
of the SEC. Shares of our common stock subject to options or
warrants currently exercisable or exercisable within
60 days of April 20, 2007 are deemed to be outstanding
for calculating the percentage of outstanding shares of the
person holding those options or warrants, but are not deemed
outstanding for calculating the percentage of any other person.
Percentage of beneficial ownership is based upon
113,116,350 shares of our common stock outstanding as of
April 20, 2007.
Security
Ownership of Certain Beneficial Owners
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
|
|
|
|
|
|
|
|
|
|
|
|
Assuming Conversion
|
|
|
|
|
|
|
|
|
|
|
|
of all Outstanding
|
|
|
|
|
|
|
|
|
Percentage of
|
|
|
Series C Preferred
|
|
Title of
|
|
Name and Address or
|
|
|
|
|
Outstanding Common
|
|
|
Stock into Common
|
|
Class
|
|
Beneficial Owner
|
|
Number of Shares
|
|
|
Shares
|
|
|
Stock
|
|
|
Common Stock
|
|
The Frost Group, LLC (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4400 Biscayne Blvd.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Suite 1500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Miami, Florida 33137
|
|
|
20,286,704
|
|
|
|
17.20
|
%
|
|
|
12.39
|
%
|
Common Stock
|
|
Frost Gamma Investments Trust (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4400 Biscayne Blvd.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Suite 1500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Miami, Florida 33137
|
|
|
66,047,216
|
|
|
|
54.60
|
%
|
|
|
39.61
|
%
|
Common Stock
|
|
Johnson and Johnson Development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporation (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
One Johnson & Johnson Plaza
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New Brunswick, NJ 08933
|
|
|
16,125,774
|
|
|
|
12.48
|
%
|
|
|
9.95
|
%
|
Common Stock
|
|
Psilos Group Partners II-S (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
625 Avenue of the Americas
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4th Floor
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10011
|
|
|
11,340,501
|
|
|
|
9.11
|
%
|
|
|
7.04
|
%
|
Common Stock
|
|
OZ Master Fund, Ltd. (OZMD) (5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9 W. 57th Street, 39th Floor
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10019
|
|
|
9,553,586
|
|
|
|
7.79
|
%
|
|
|
5.95
|
%
|
|
|
|
(1) |
|
The Frost Group, LLC holds 15,490,546 shares of the
Companys common stock and warrants to purchase
6,487 shares of the Companys Series C Preferred
Stock, convertible into 648,700 shares of the
Companys common stock. The Frost Group, LLC also holds
warrants to purchase 4,147,458 shares of the Companys
common stock. |
|
(2) |
|
The Frost Gamma Investments Trust holds 36,518,923 shares
of the Companys common stock and warrants to purchase
9,241,589 shares of common stock. The number of shares
included above also includes 15,490,546 shares of common
stock, warrants to purchase 4,147,458 shares of common
stock and warrants to purchase 6,487 shares of the
Companys Series C preferred stock, convertible into
648,700 shares of the Companys common stock, owned
directly by The Frost Group, LLC. Frost Gamma Investments Trust
is a principal member of The Frost Group, LLC. Frost Gamma
Investments Trust disclaims beneficial ownership of these shares
of common stock, except to the extent of any pecuniary interest
therein. |
|
(3) |
|
Johnson and Johnson Development Corporation holds
129,736 shares of the Companys Series C
preferred stock, convertible into 12,973,600 shares of the
Companys common stock. Johnson and Johnson Development
Corporation also holds warrants to purchase
2,949,141 shares of the Companys common stock and
options to purchase 203,033 shares of the Companys
common stock that are exercisable as of April 20, 2007 or
will become exercisable on or before June 20, 2007. |
|
(4) |
|
Psilos Group Partners II-S holds 90,815 shares of the
Companys Series C preferred stock, convertible into
9,081,500 shares of the Companys common stock. Psilos
Group Partners II S also holds warrants to purchase
2,064,399 shares of the Companys common stock and
options to purchase 194,602 shares of the Companys
common stock that are exercisable as of April 20, 2007 or
will become exercisable on or before June 20, 2007. |
|
(5) |
|
OZ Master Fund, Ltd. holds 77,841 shares of the
Companys Series C preferred stock, convertible into
7,784,100 shares of the Companys common stock. OZ
Master Fund, Ltd. also holds warrants to purchase
1,769,486 shares of the Companys common stock that
are exercisable as of April 20, 2007. |
2
Security
Ownership of Directors and Named Executive Officers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of
|
|
|
|
|
|
|
|
|
|
|
|
Common Shares
|
|
|
|
|
|
|
|
|
|
|
|
Assuming Conversion
|
|
|
|
|
|
|
|
|
|
|
|
of all Outstanding
|
|
|
|
|
|
|
|
|
Percentage of
|
|
|
Series C Preferred
|
|
Title of
|
|
Name of
|
|
Number of Outstanding
|
|
|
Outstanding Common
|
|
|
Stock into Common
|
|
Class
|
|
Beneficial Owner
|
|
Shares Beneficially Owned
|
|
|
Shares
|
|
|
Stock
|
|
|
Common Stock
|
|
Phillip Frost, M.D.
|
|
|
66,047,216
|
(1)
|
|
|
54.60
|
%
|
|
|
39.61
|
%
|
Common Stock
|
|
Jane H. Hsiao, Ph.D., MBA
|
|
|
14,540,724
|
(2)
|
|
|
12.53
|
%
|
|
|
8.99
|
%
|
Common Stock
|
|
David Eichler
|
|
|
11,340,501
|
(3)
|
|
|
9.11
|
%
|
|
|
7.04
|
%
|
Common Stock
|
|
Steven D. Rubin
|
|
|
5,132,021
|
(4)
|
|
|
4.50
|
%
|
|
|
3.21
|
%
|
Common Stock
|
|
Dale Pfost, Ph.D.
|
|
|
4,854,113
|
(5)
|
|
|
4.17
|
%
|
|
|
3.01
|
%
|
Common Stock
|
|
Samuel Reich
|
|
|
1,400,439
|
(6)
|
|
|
1.23
|
%
|
|
|
0.88
|
%
|
Common Stock
|
|
Michael Reich
|
|
|
649,145
|
(7)
|
|
|
*
|
|
|
|
*
|
|
Common Stock
|
|
Denis OShaughnessy, Ph.D.
|
|
|
440,127
|
(8)
|
|
|
*
|
|
|
|
*
|
|
Common Stock
|
|
Robert Baron
|
|
|
121,800
|
(9)
|
|
|
*
|
|
|
|
*
|
|
Common Stock
|
|
John A. Paganelli
|
|
|
155,000
|
(10)
|
|
|
*
|
|
|
|
*
|
|
Common Stock
|
|
Adam Logal
|
|
|
16,216
|
(11)
|
|
|
*
|
|
|
|
*
|
|
Common Stock
|
|
Richard A. Lerner, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
Melvin L. Rubin, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
All Executive Officers and
Directors as a group
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(12 persons)
|
|
|
104,451,240
|
|
|
|
87.36
|
%
|
|
|
63.60
|
%
|
|
|
|
* |
|
less than 1%. |
|
(1) |
|
The number of shares beneficially owned by Dr. Frost
includes shares of common stock and warrants to purchase shares
of common stock held by or beneficially owned by Frost Gamma
Investments Trust, of which Frost Gamma Limited Partnership is
the sole and exclusive beneficiary. Dr. Frost is one of two
limited partners of Frost Gamma, L.P. The general partner of
Frost Gamma, L.P. is Frost Gamma, Inc. and the sole shareholder
of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost
is also the sole shareholder of Frost-Nevada Corporation. The
Frost Gamma Investments Trust holds 36,518,923 shares of
the Companys common stock and warrants to purchase
9,241,589 shares of common stock. The number of shares
included above also includes 15,490,546 shares of common
stock, warrants to purchase 4,147,458 shares of common
stock and warrants to purchase 6,487 shares of the
Companys Series C preferred stock, convertible into
648,700 shares of the Companys common stock, owned
directly by The Frost Group, LLC. Frost Gamma Investments Trust
disclaims beneficial ownership of these shares of common stock,
except to the extent of any pecuniary interest therein. |
|
(2) |
|
Dr. Hsiao is a member of The Frost Group, LLC.
Dr. Hsiao disclaims beneficial ownership of the securities
held by The Frost Group, except to the extent of her pecuniary
interest therein. |
|
(3) |
|
Includes 11,145,899 shares and warrants and 138,384 options
that are exercisable as of April 20, 2007 or will become
exercisable on or before June 20, 2007 and which are held
by Psilos Group Partners II-S, an entity with which
Mr. Eichler is affiliated. Mr. Eichler disclaims
beneficial ownership of all such shares, warrants and options. |
|
(4) |
|
Mr. Rubin is a member of The Frost Group, LLC.
Mr. Rubin disclaims beneficial ownership of the securities
held by The Frost Group, except to the extent of his pecuniary
interest therein. |
|
(5) |
|
Includes 1,644,828 shares which are the subject of stock
options that are exercisable as of April 20, 2007 or will
become exercisable on or before June 20, 2007. |
|
(6) |
|
Includes 864,868 shares which are the subject of stock
options that are exercisable as of April 20, 2007 or will
become exercisable on or before June 20, 2007. Excludes
330,254 shares beneficially owned by Ilana K. Reich, of
which Mr. Samuel |
|
(7) |
|
J. Reich disclaims beneficial ownership. Includes
256,875 shares which are the subject of stock options that
are exercisable as of April 20, 2007 or will become
exercisable on or before June 20, 2007. |
|
(8) |
|
Includes 440,127 shares which are the subject of stock
options that are exercisable as of April 20, 2007 or will
become exercisable on or before June 20, 2007. |
3
|
|
|
(9) |
|
Includes 55,000 shares which are the subject of stock
options that are exercisable as of April 20, 2007 or will
become exercisable on or before June 20, 2007. |
|
(10) |
|
Includes 55,000 shares which are the subject of stock
options that are exercisable as of April 20, 2007 or will
become exercisable on or before June 20, 2007. |
|
(11) |
|
Includes 16,216 shares which are the subject of stock
options that are exercisable as of April 20, 2007 or will
become exercisable on or before June 20, 2007. |
CORPORATE
GOVERNANCE
Corporate
Governance Policy
We will regularly monitor developments in the area of corporate
governance and review our processes and procedures in light of
such developments. In those efforts, we review Federal laws
affecting corporate governance, such as the Sarbanes-Oxley Act
of 2002. In addition, in anticipation of our application to list
our shares of common stock on the American Stock Exchange (the
AMEX), we also review applicable rules of the AMEX.
Board of
Directors Meetings
Our business, property and affairs are managed under the
direction of our board of directors. Members of our board of
directors are kept informed of our business through discussions
with our Chairman and Chief Executive Officer, President, Chief
Accounting Officer and other officers and employees, by
reviewing materials provided to them and by participating in
meetings of our board of directors and its committees.
Our board of directors met 14 times during 2006: 10 of
which were at regularly scheduled meetings and 4 of which were
at special meetings. During 2006, the committees of our board of
directors held a total of 4 meetings. Each director attended at
least 75% of the total number of meetings of the board of
directors and each committee of the board on which such director
served.
Independence
Determination
Our board of directors will observe all applicable criteria for
independence established by the AMEX and other governing laws
and applicable regulations. No director is deemed to be
independent unless our board of directors determines that the
director has no relationship which would interfere with the
exercise of independent judgment in carrying out his or her
responsibilities as a director. Our board of directors has
determined that the following directors are independent as
determined by listing standards of the AMEX and other applicable
regulations: Robert Baron, David A. Eichler, Richard A. Lerner,
M.D., Michael Reich and Melvin L. Rubin, M.D.
In making this determination, the board of directors considered
all relevant factors, including the fact that Michael Reich is
the uncle of Samuel Reich, the Companys Executive Vice
President.
Standing
Committees of the Board of Directors
Our board of directors maintains several standing committees,
including an audit committee established in accordance with
section 3(a)(58)(A) of the Securities Exchange Act of 1934,
as amended (Exchange Act), a compensation committee, and a
corporate governance and nominating committee. These committees
and their functions are described below. Our board of directors
may also establish various other committees to assist it in its
responsibilities.
Our board of directors has adopted a written charter for each of
its standing committees. The full text of each charter is
available on our website at http://www.opko.com.
4
The following table shows the current members (indicated by an
X or Chair) of each of our standing
board committees:
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate
|
|
|
|
|
|
|
Governance and
|
|
|
Audit
|
|
Compensation
|
|
Nominating
|
|
Phillip Frost, M.D.
|
|
|
|
|
|
|
Jane H. Hsiao, Ph.D., MBA
|
|
|
|
|
|
|
Robert Baron
|
|
X
|
|
|
|
X
|
David A. Eichler
|
|
Chair
|
|
X
|
|
|
Richard A. Lerner, M.D.
|
|
|
|
Chair
|
|
X
|
John A. Paganelli
|
|
|
|
|
|
|
Michael Reich
|
|
X
|
|
|
|
|
Melvin L. Rubin, M.D.
|
|
|
|
X
|
|
Chair
|
Steven D. Rubin
|
|
|
|
|
|
|
Audit
Committee
Our audit committee oversees our corporate accounting and
financial reporting processes. Our audit committee:
|
|
|
|
|
evaluates the qualifications, independence and performance of
our registered independent public accounting firm;
|
|
|
|
determines the engagement of our registered independent public
accounting firm;
|
|
|
|
approves the retention of our registered independent public
accounting firm to perform any proposed permissible non-audit
services;
|
|
|
|
ensures the rotation of the partners of our registered
independent public accounting firm on our engagement team as
required by law;
|
|
|
|
reviews our systems of internal controls established for
finance, accounting, legal compliance and ethics;
|
|
|
|
reviews our accounting and financial reporting processes;
|
|
|
|
provides for effective communication between our board of
directors, our senior and financial management and our
independent auditors;
|
|
|
|
discusses with management and our independent auditors the
results of our annual audit and the review of our quarterly
financial statements;
|
|
|
|
reviews the audits of our financial statements;
|
|
|
|
implements a pre-approval policy for certain audit and non-audit
services performed by our registered independent public
accounting firm; and
|
|
|
|
reviews and approves any related party transactions that we are
involved in.
|
Our audit committee is comprised of Messrs., Eichler, Reich and
Baron. Our board of directors has determined that
Mr. Eichler is an audit committee financial
expert as currently defined under the SECs rules
implementing Section 407 of the Sarbanes-Oxley Act of 2002.
We believe that the composition and functioning of our audit
committee complies with all applicable requirements of the
Sarbanes-Oxley Act of 2002, the AMEX and the SECs rules
and regulations, including those regarding the independence of
our audit committee members. We intend to comply with future
requirements to the extent that they become applicable to us.
On April 25, 2007, the board of directors amended and
restated the Companys Audit Committee Charter.
5
Compensation
Committee
Our compensation committee administers the compensation program
for our executive officers. Our compensation committee reviews
and either approves, on behalf of the board of directors, or
recommends to the board of directors for approval,
(i) annual salaries, bonuses, and other compensation for
our executive officers, and (ii) individual equity awards
for our employees and executive officers. Our compensation
committee also oversees our compensation policies and practices.
Our compensation committee also performs the following functions
related to executive compensation:
|
|
|
|
|
coordinates the board of directors role in establishing
performance criteria for executive officers;
|
|
|
|
annually evaluates each of our executive officers
performance;
|
|
|
|
reviews and approves the annual salary, bonus, stock options and
other benefits, direct and indirect, of our executive officers,
including our Chief Executive Officer;
|
|
|
|
reviews and recommends new executive compensation programs;
|
|
|
|
annually reviews the operation and efficacy of our executive
compensation programs;
|
|
|
|
periodically reviews that executive compensation programs
comport with the compensation committees stated
compensation philosophy;
|
|
|
|
establishes and periodically reviews policies in the area of
senior management perquisites;
|
|
|
|
reviews and recommends to the board of directors the appropriate
structure and amount of compensation for our directors;
|
|
|
|
reviews and approves material changes in our employee benefit
plans;
|
|
|
|
administers our equity compensation and employee stock purchase
plans; and
|
|
|
|
reviews the adequacy of the compensation committee and its
charter and recommends any proposed changes to the board of
directors not less than annually.
|
In deciding upon the appropriate level of compensation for our
executive officers, the compensation committee regularly reviews
our compensation programs relative to our strategic objectives
and emerging market practice and other changing business and
market conditions. In addition, the compensation committee also
takes into consideration the recommendations of our Chief
Executive Officer concerning compensation actions for our other
executive officers and any recommendations of compensation
consultants. The primary role of consultants is to provide
objective data, analysis and advice to the compensation
committee. In providing data and recommendations to the
compensation committee, our consultants work with our Chief
Executive Officer and management to obtain information needed to
carry out its assignments.
Our compensation committee is comprised of Dr. Rubin,
Dr. Lerner and Mr. Eichler. We believe that the
composition and functioning of our compensation committee
complies with all applicable requirements of the Sarbanes-Oxley
Act of 2002, the AMEX and the SECs rules and regulations,
including those regarding the independence of our compensation
committee members. We intend to comply with future requirements
to the extent that they become applicable to us.
On April 25, 2007, the board of directors amended and
restated the Companys Compensation Committee Charter.
Corporate
Governance and Nominating Committee
Our corporate governance and nominating committees
responsibilities include the selection of potential candidates
for our board of directors. It also makes recommendations to our
board of directors concerning the structure and membership of
the other board committees and considers director candidates
recommended by others, including our Chief Executive Officer,
other board members, third parties and shareholders. Our
corporate governance and nominating committee is comprised of
Dr. Rubin, Dr. Lerner and Mr. Baron. We believe
that
6
the composition of our nominating and governance committee
complies with any applicable requirements of the Sarbanes-Oxley
Act of 2002, the AMEX and the SECs rules and regulations,
including those regarding the independence of our nominating and
governance committee members. We intend to comply with future
requirements to the extent that they become applicable to us.
The corporate governance and nominating committee will identify
director nominees through a combination of referrals, including
by stockholders, existing members of the board of directors and
management, and direct solicitations, where warranted. Once a
candidate has been identified, the corporate governance and
nominating committee reviews the individuals experience
and background, and may discuss the proposed nominee with the
source of the recommendation. The corporate governance and
nominating committee usually believes it to be appropriate for
committee members to interview the proposed nominee before
making a final determination whether to recommend the individual
as a nominee to the entire board of directors to stand for
election to the board of directors.
On April 25, 2007, the board of directors amended and
restated the Companys Corporate Governance and Nominating
Committee Charter.
Director
Nomination Process
The corporate governance and nominating committee will review
annually and make recommendations to the board of directors
regarding the appropriate qualifications, skills and experience
expected of individual members and of the board of directors as
a whole with the objective of having a board of directors with
sound judgment and diverse backgrounds and experience to
represent stockholder interests.
The corporate governance and nominating committee believes that
nominees for election to the board of directors should possess
sufficient business or financial experience and a willingness to
devote the time and effort necessary to discharge the
responsibilities of a director. This experience can include, but
is not limited to, service on other boards of directors or
active involvement with other boards of directors, experience in
the industries in which the Company conducts its business, audit
and financial expertise, clinical experience, operational
experience, or a scientific or medical background. The corporate
governance and nominating committee does not believe that
nominees for election to the board of directors should be
selected through mechanical application of specified criteria.
Rather, the corporate governance and nominating committee
believes that the qualifications and strengths of individuals
should be considered in their totality with a view to nominating
persons for election to the board of directors whose
backgrounds, integrity, and personal characteristics indicate
that they will make a positive contribution to the board of
directors.
The corporate governance and nominating committee intends to
identify candidates for election to the board of directors
through the personal knowledge and experience of the members of
the Committee, through third-party recommendations, and, for so
long as the Committee believes it appropriate, through a search
firm selected by the corporate governance and nominating
committee and compensated by the Company. Candidates will be
evaluated based upon their backgrounds and interviews with
members of the board of directors. The Committee does not plan
to evaluate candidates identified by the corporate governance
and nominating committee differently from those recommended by a
stockholder or otherwise.
The corporate governance and nominating committee will consider
director candidates recommended by stockholders. Stockholders
who wish to recommend candidates for election to the board of
directors must do so in writing. The recommendation should be
sent to the Secretary of the Company, Adam Logal, Opko Health,
Inc., 4400 Biscayne Boulevard, Suite 900, Miami, Florida
33137, who will forward the recommendation to the Committee. The
recommendation must set forth (i) the name and address as
they appear on the Companys books of the stockholder
making the recommendation and the class and number of shares of
capital stock of the Company beneficially owned by such
stockholder and (ii) the name of the candidate and all
information relating to the candidate that is required to be
disclosed in solicitations of proxies for election of directors
under the federal proxy rules. The recommendation must be
accompanied by the candidates written consent to being
named in the Companys proxy statement as a nominee for
election to the board of directors and to serving as a director,
if elected.
7
Stockholders must also comply with all requirements of the
Companys by-laws with respect to nomination of persons for
election to the board of directors.
Compensation
Committee Interlocks and Insider Participation
The current members of our compensation committee are
Dr. Rubin, Dr. Lerner and Mr. Eichler. None of
these individuals was at any time since January 1, 2006 or
at any time prior thereto an officer or employee of ours. In
addition, none of our executive officers serves as a member of
the board of directors or compensation committee of any entity
that has one or more executive officers serving as a member of
our board of directors or compensation committee.
Stockholder
Communications Policy
Stockholders may initiate in writing any communication with our
board of directors or any individual director by sending the
correspondence to our Secretary, Opko Health, Inc., 4400
Biscayne Blvd, Suite 900, Miami, Florida 33137, Attention:
Adam Logal, Secretary. This centralized process assists our
board of directors in reviewing and responding to stockholder
communications in an appropriate manner.
Board
Attendance at Annual Meetings of Stockholders
Although we encourage each member of our board of directors to
attend our annual meetings of stockholders, we do not have a
formal policy requiring the members of our board of directors to
attend.
Code of
Business Conduct and Ethics
On April 25, 2007, we adopted a Code of Business Conduct
and Ethics. We require all employees, including our principal
executive officer and principal accounting officer and other
senior officers and our employee directors, to read and to
adhere to the Code of Business Conduct and Ethics in discharging
their work-related responsibilities. Employees are required to
report any conduct that they believe in good faith to be an
actual or apparent violation of the Code of Business Conduct and
Ethics. The Code of Business Conduct and Ethics is available on
our website at http://www.opko.com.
COMPENSATION
DISCUSSION AND ANALYSIS
The primary goals of our board of directors with respect to
executive compensation will be to attract and retain talented
and dedicated executives, to tie annual and long-term cash and
stock incentives to achievement of specified performance
objectives, and to create incentives which will result in
stockholder value creation. To achieve these goals, we have
formed a compensation committee to recommend executive
compensation packages to our board of directors that are
generally based on a mix of salary, discretionary bonus and
equity awards. Although we have not adopted any formal
guidelines for allocating total compensation between equity
compensation and cash compensation, we intend to implement and
maintain compensation plans that tie a substantial portion of
our executives overall compensation to achievement of
corporate goals.
Benchmarking
of Cash and Equity Compensation
We have not retained a compensation consultant to review our
policies and procedures with respect to executive compensation.
We have, in the past, conducted an annual benchmark review of
the aggregate level of our executive compensation, as well as
the mix of elements used to compensate our executive officers.
This review is based on a survey of executive compensation paid
by peer companies in the pharmaceutical industry of similar size
and stage of development. In addition, we have historically
taken into account input from other independent members of our
board of directors and publicly available data relating to the
compensation practices and policies of other companies within
and outside our industry.
We may retain the services of third-party executive compensation
specialists from time to time in connection with the
establishment of cash and equity compensation and related
policies.
8
Elements
of Compensation
We will evaluate individual executive performance with a goal of
setting compensation at levels the board or any applicable
committee thereof believes are comparable with executives in
other companies of similar size and stage of development while
taking into account our relative performance and our own
strategic goals. The compensation received by our executive
officers consists of the following elements:
Base Salary. Base salaries for our
executives are established based on the scope of their
responsibilities and individual experience, taking into account
competitive market compensation paid by other companies for
similar positions within the pharmaceutical industry. The table
below sets forth the base salary for our Named Executive
Officers:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Salary
|
|
Name
|
|
Principal Position
|
|
2005
|
|
|
2006
|
|
|
2007
|
|
|
Phillip Frost, M.D.
|
|
Chairman and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam Logal
|
|
Executive Director of Finance,
|
|
|
|
|
|
|
|
|
|
$
|
140,000
|
|
|
|
Chief Accounting Officer, Treasurer
and Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
Dale Pfost, PhD
|
|
President
|
|
$
|
265,000
|
|
|
$
|
280,000
|
|
|
$
|
325,000
|
|
Samuel Reich
|
|
Executive Vice President
|
|
$
|
156,925
|
|
|
$
|
172,000
|
|
|
$
|
210,000
|
|
Denis OShaughnessy
|
|
Senior Vice President of Clinical
|
|
|
|
|
|
|
|
|
|
$
|
265,000
|
|
|
|
Development
|
|
|
|
|
|
|
|
|
|
|
|
|
Discretionary Annual Bonus. In addition
to base salaries, our compensation committee has the authority
to award discretionary annual bonuses to our executive officers.
The annual incentive bonuses are intended to compensate officers
for achieving corporate goals and value-creating milestones.
Each executive officer is eligible for a discretionary annual
bonus up to an amount equal to a specified percentage of such
executive officers salary.
2006 Cash
Incentive Plan Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actual Bonus as
|
|
|
Target Payout as a
|
|
|
|
|
|
|
|
|
Percentage of Base
|
|
|
Percentage of Base
|
|
|
|
|
Name
|
|
Actual Bonus Award
|
|
Salary
|
|
|
Salary
|
|
|
Target Bonus Award
|
|
|
Phillip Frost, M.D.
|
|
Chairman and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam Logal
|
|
Executive Director of Finance,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Accounting Officer,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Treasurer and Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
Dale Pfost, PhD
|
|
President
|
|
|
21
|
%
|
|
|
30
|
%
|
|
$
|
60,000
|
|
Samuel Reich
|
|
Executive Vice President
|
|
|
23
|
%
|
|
|
30
|
%
|
|
$
|
40,000
|
|
Denis OShaughnessy
|
|
Senior Vice President of Clinical
Development
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term Incentive Program. We believe
that long-term performance is achieved through an ownership
culture that encourages such performance by our executive
officers through the use of stock and stock-based awards. We
believe that the use of equity and equity-based awards offers
the best approach to achieving our compensation goals. We have
not adopted formal stock ownership guidelines.
Severance and
Change-in-Control
Benefits. Certain of our named executive
officers are entitled to certain severance and change of control
benefits, the terms of which are described below under
Employment Agreements and Change in Control
Arrangements. We believe these severance and
change-in-control
benefits are an essential element of our executive compensation
package and assist us in recruiting and retaining talented
individuals.
Restricted Stock Grants or Awards. We
did not grant any restricted stock or restricted stock awards
pursuant to our equity benefit plans to any of our executive
officers in the year ended December 31, 2006. However, our
compensation committee, in its discretion, may in the future
elect to make such grants to our executive officers if it deems
it advisable.
9
Other Compensation. We intend to
continue to maintain the current benefits and perquisites for
our executive officers; however, our compensation committee, in
its discretion, may in the future revise, amend or add to the
benefits and perquisites of any executive officer if it deems it
advisable. The material terms of our employment agreements with
our named executive officers are described below under
Employment Agreements and Change in Control
Arrangements.
Summary
Compensation Table
The following table sets forth a summary for the fiscal year
ended December 31, 2006 of the cash and non-cash
compensation awarded, paid or accrued by the Company to our
Named Executive Officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Award(s)
|
|
|
Option Award(s)
|
|
|
All Other
|
|
|
|
|
Name and Principal Position
|
|
Year
|
|
|
Salary ($)
|
|
|
Bonus ($)
|
|
|
($)
|
|
|
($)
|
|
|
Compensation ($)
|
|
|
Total ($)
|
|
|
John A. Paganelli(1)
|
|
|
2006
|
|
|
|
25,000
|
|
|
|
|
|
|
|
|
|
|
|
810
|
|
|
$
|
75,000
|
(2)
|
|
|
100,810
|
|
Interim Chief Executive
Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Phillip Frost, M.D.(3)
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive
Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dale Pfost, Ph.D.
|
|
|
2006
|
|
|
|
280,000
|
|
|
|
84,000
|
|
|
|
|
|
|
|
359,982
|
|
|
|
|
|
|
|
723,982
|
|
President
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam Logal
|
|
|
2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Director of Finance
and Chief Accounting Officer, Treasurer and
Secretary(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Samuel J. Reich
|
|
|
2006
|
|
|
|
172,000
|
|
|
|
51,600
|
|
|
|
|
|
|
|
193,470
|
|
|
|
|
|
|
|
417,070
|
|
Executive Vice President
(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denis OShaughnessy(7)(8)
|
|
|
2006
|
|
|
|
47,702
|
|
|
|
45,520
|
|
|
|
|
|
|
|
21,564
|
|
|
|
|
|
|
|
114,786
|
|
Senior Vice President of
Clinical Development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Mr. Paganelli served as the Companys interim Chief
Executive Officer from June 29, 2005 and he resigned from
this position upon the consummation of the Acquisition. |
|
(2) |
|
Includes $75,000 of director fees for Mr. Paganelli. |
|
(3) |
|
Dr. Frost became the Companys Chief Executive Officer
upon consummation of the Acquisition. |
|
(4) |
|
Dr. Pfost served as the President and Chief Executive
Officer of Acuity prior to the Acquisition and was appointed to
be the Companys President on March 29, 2007. |
|
(5) |
|
Mr. Logal served as the Executive Director of Finance and
Chief Accounting Officer of Acuity prior to the Acquisition and
was appointed to be the Companys Executive Director of
Finance, Chief Accounting Officer and Treasurer on
March 29, 2007. |
|
(6) |
|
Samuel Reich served as the Executive Vice President of Acuity
prior to the Acquisition and was appointed to be the
Companys Executive Vice President on March 29, 2007. |
|
(7) |
|
Dr. OShaughnessy served as the Senior Vice President
of Clinical Development of Acuity prior to the Acquisition and
was appointed to be the Companys Senior Vice President of
Clinical Development on March 29, 2007. |
|
(8) |
|
Dr. OShaughnessy commenced employment with Acuity on
November 13, 2006. |
Grants of
Plan-Based Awards in 2006
The following table presents information concerning grants of
plan-based awards to each of the named executive officers during
the year ended December 31, 2006. The exercise price per
share of each option granted to
10
our named executive officers was equal to the fair market value
of our common stock, as determined by our compensation committee
on the date of the grant.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant Date
|
|
|
|
|
|
|
Number of Securities
|
|
|
Exercise Price
|
|
|
Fair Value of
|
|
Name
|
|
Grant Date
|
|
|
Underlying Options
|
|
|
Per Share
|
|
|
Option Awards (1)
|
|
|
Phillip Frost, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dale Pfost, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John A. Paganelli
|
|
|
1/3/2006
|
|
|
|
5,000
|
|
|
$
|
0.41
|
|
|
$
|
205
|
|
|
|
|
4/3/2006
|
|
|
|
5,000
|
|
|
$
|
0.41
|
|
|
$
|
205
|
|
|
|
|
7/3/2006
|
|
|
|
5,000
|
|
|
$
|
0.41
|
|
|
$
|
205
|
|
Adam Logal
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Samuel J. Reich
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denis OShaughnessy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Amounts reflect the total fair value of stock options granted in
2006, calculated in accordance with
SFAS No. 123®. |
Outstanding
Equity Awards at Fiscal Year-End
The following table sets forth information with respect to the
Named Executive Officers concerning equity awards granted by the
Company as of December 31, 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
|
|
Stock Awards
|
|
|
|
Number of Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
Number of Shares or
|
|
|
Market Value of
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
Units of Stock That
|
|
|
Shares or Units of
|
|
|
|
Unexercised Options (#)
|
|
|
Unexercised Options
|
|
|
Option Exercise
|
|
|
Option Expiration
|
|
|
Have Not Vested
|
|
|
Stock That Have Not
|
|
Name
|
|
Exercisable (1)
|
|
|
(#) Unexercisable
|
|
|
Price ($)
|
|
|
Date
|
|
|
(#)
|
|
|
Vested ($)
|
|
|
Phillip Frost, M.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dale Pfost, Ph.D.
|
|
|
77,841
|
|
|
|
233,524
|
|
|
|
0.05
|
|
|
|
01/01/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
90,815
|
|
|
|
220,550
|
|
|
|
0.05
|
|
|
|
11/01/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
608,138
|
|
|
|
689,223
|
|
|
|
0.04
|
|
|
|
02/15/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
225,740
|
|
|
|
|
|
|
|
0.04
|
|
|
|
09/24/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
323,042
|
(2)
|
|
|
107,680
|
|
|
|
0.04
|
|
|
|
12/11/2013
|
|
|
|
|
|
|
|
|
|
John A. Paganelli
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.41
|
|
|
|
07/03/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.41
|
|
|
|
04/03/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.41
|
|
|
|
01/03/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.45
|
|
|
|
10/4/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.42
|
|
|
|
7/1/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.40
|
|
|
|
4/1/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.32
|
|
|
|
1/3/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.67
|
|
|
|
10/1/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
(2)
|
|
|
|
|
|
|
0.71
|
|
|
|
7/1/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
(2)
|
|
|
|
|
|
|
0.89
|
|
|
|
4/27/2014
|
|
|
|
|
|
|
|
|
|
Adam Logal
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Samuel J. Reich
|
|
|
71,920
|
|
|
|
215,766
|
|
|
|
0.05
|
|
|
|
01/01/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
83,907
|
|
|
|
203,778
|
|
|
|
0.05
|
|
|
|
11/01/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
214,063
|
|
|
|
242,605
|
|
|
|
0.04
|
|
|
|
02/15/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
131,360
|
|
|
|
102,169
|
|
|
|
0.04
|
|
|
|
09/21/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
194,603
|
|
|
|
64,867
|
|
|
|
0.04
|
|
|
|
12/11/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
32,433
|
|
|
|
745,980
|
|
|
|
0.06
|
|
|
|
10/23/2016
|
|
|
|
|
|
|
|
|
|
Denis OShaughnessy
|
|
|
259,471
|
(2)
|
|
|
|
|
|
|
0.06
|
|
|
|
10/23/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Except as noted below, all options vest in 48 equal monthly
installments beginning on the date of grant. |
|
(2) |
|
This option was fully vested on the grant date. |
11
Director
Compensation
The following table sets forth information with respect to
compensation of directors of the Company during fiscal year 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
Fees Earned or Paid
|
|
|
|
|
|
Option
|
|
|
Incentive Plan
|
|
|
Compensation
|
|
|
All Other
|
|
|
|
|
|
|
in Cash
|
|
|
Stock Award
|
|
|
Awards
|
|
|
Compensation
|
|
|
Earnings
|
|
|
Compensation
|
|
|
Total
|
|
Name
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
Robert Baron
|
|
|
50,000
|
|
|
|
|
|
|
|
810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,810
|
|
David A, Eichler
|
|
|
|
|
|
|
|
|
|
|
13,815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,815
|
|
Michael Reich(1)
|
|
|
|
|
|
|
|
|
|
|
46,960
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
46,960
|
|
Steven D. Rubin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jane H. Hsiao, Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Paganelli
|
|
|
25,000
|
|
|
|
|
|
|
|
810
|
|
|
|
|
|
|
|
|
|
|
$
|
75,000
|
|
|
|
100,810
|
|
Richard Lerner, MD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Melvin Rubin, MD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
At December 31, 1006, Michael Reich had outstanding options
to purchase 291,644 shares of our Common Stock. |
We are currently considering compensation policies for directors
of the Company. In the future, we may adopt a policy of paying
independent directors an annual retainer and a fee for
attendance at board and committee meetings. We anticipate
reimbursing each director for reasonable travel expenses related
to such directors attendance at board of directors and
committee meetings.
Employment
Agreements and Change in Control Arrangements
Samuel J. Reich. We are employing
Samuel J. Reich as our Executive Vice President. Under his
employment agreement, Mr. Reich receives an annual base
salary, subject to increases upon an annual review by our board
of directors. Mr. Reichs current salary is $210,000.
The agreement provides for a discretionary annual bonus based on
Mr. Reichs performance and our business results as
determined by our board of directors. Under the agreement,
either we or Mr. Reich may terminate his employment at any
time, subject to continuation of salary payment and benefits for
12 months if we terminate Mr. Reichs employment
without cause, if Mr. Reich terminates his employment for
good reason or if we give Mr. Reich notice of our intent
not to renew the agreement after the initial year of his
employment with the Company. The employment period will
automatically be extended for one additional year unless either
the Company or Mr. Reich shall have given to the other
party written notice of non-extension at least thirty
(30) days prior to such anniversary. We have agreed to
grant Mr. Reich an option to purchase 500,000 shares
of our common stock upon the implementation of our 2007 Equity
Incentive Plan.
Denis OShaughnessy, Ph.D. We are
employing Dr. OShaughnessy as our Senior Vice
President of Clinical Development. We have entered into a
severance agreement with Dr. OShaughnessy which
provides that if we terminate his employment without cause
during his first year of employment, we are obligated to pay him
severance equal to three months salary following termination.
The severance period increases by three months after each year
of employment up to twelve months. We have also agreed to
continue vesting of his options during the applicable severance
period.
Adam Logal. We are employing Adam Logal
as our Executive Director of Finance, Chief Accounting Officer,
Treasurer and Secretary. We have agreed to enter into a
severance agreement with Mr. Logal to provide that:
Mr. Logal will receive four months of paid salary and
continued benefits if he is terminated without cause or he
terminates his employment for good reason. Upon such
termination, we have agreed to accelerate the vesting of all
unvested stock options granted to Mr. Logal in connection
with the commencement of his employment.
12
If we terminated our named executive officers without cause or
they resigned for good reason on December 31, 2006, we
would have to make the payments set forth in the following chart:
|
|
|
|
|
|
|
|
|
|
|
Cash Payments upon
|
|
|
|
|
|
|
Termination without
|
|
|
|
|
|
|
Cause or
|
|
|
|
|
|
|
Resignation for
|
|
|
|
|
Name and Principal Position
|
|
Good Reason
|
|
|
Vesting of Stock Options
|
|
|
John A. Paganelli(1)
|
|
|
None
|
|
|
|
None
|
|
Interim Chief Executive
Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Phillip Frost, M.D.
|
|
|
None
|
|
|
|
None
|
|
Chief Executive
Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adam Logal(2)
|
|
|
None
|
|
|
|
None
|
|
Executive Director of Finance
and Chief Accounting Officer, Treasurer and Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Samuel J. Reich
|
|
$
|
210,000
|
|
|
|
376,394
|
|
Executive Vice
President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denis OShaughnessy
|
|
$
|
88,333
|
|
|
|
48,650
|
|
Senior Vice President of
Clinical Development
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Mr. Paganelli served as the Companys interim Chief
Executive Officer from June 29, 2005 and he resigned from
this position upon the consummation of the Acquisition. |
|
(2) |
|
Mr. Logal joined the Company on March 15, 2007. |
RATIFICATION
OF SELECTION OF INDEPENDENT AUDITOR
On April 9, 2007, the Board of Directors of the Company
approved the decision to engage Ernst & Young LLP as
the Companys independent registered public accounting firm
to audit our financial statements for fiscal year ending
December 31, 2007 and the decision to dismiss of
Rotenberg & Co., LLP. Rotenberg & Co., LLP
served as our independent auditors for 2006. The stockholders,
acting by majority written consent, ratified this appointment of
Ernst & Young LLP as the Companys independent
registered public accounting firm effective
May , 2007.
For purposes of determining whether to select Ernst &
Young LLP as the independent registered public accounting firm
to perform the audit of our financial for 2007, our board of
directors conducted a thorough review of Ernst & Young
LLP. In the course of assisting the board in its review, company
representatives interviewed senior management of
Ernst & Young.
The board of directors considered:
|
|
|
|
|
The quality of the proposed Ernst & Young engagement
team and Ernst & Youngs experience, client
service, responsiveness and technical expertise.
|
|
|
|
Ernst & Youngs leadership, management structure,
client and employee retention and compliance and ethics programs.
|
|
|
|
The record of Ernst & Young against comparable
accounting firms in various matters, including those specific to
the life science industry.
|
|
|
|
Ernst & Youngs financial strength and performance.
|
|
|
|
The appropriateness of fees charged.
|
Regarding
the Former Independent Auditor.
The reports of Rotenberg & Co. for the fiscal years
ended December 31, 2006 and 2005 did not contain any
adverse opinion or disclaimer of opinion and were not modified
or qualified as to uncertainty, audit scope, or accounting
principles. From September 23, 2005 through the end of the
fiscal year ended December 31, 2006, there were no
disagreements with Rotenberg & Co. on any matter of
accounting principles or practices, financial
13
statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of
Rotenberg & Co., would have caused Rotenberg &
Co. to make reference to the subject matter of the disagreements
in connection with its report and there were no reportable
events as defined in Item 304(a)(1)(v) of
Regulation S-K.
On April 9, 2007, the Company requested that
Rotenberg & Co. furnish it with a letter addressed to
the Securities and Exchange Commission stating whether or not it
agrees with the above statements. A copy of such letter, dated
April 11, 2007, was filed as an exhibit to a
Form 8-K
filed by the Company on April 13, 2007.
Regarding
the Newly-Engaged Independent Auditor
During the fiscal years ended December 31, 2005 and 2006
and during the current fiscal year through April 9, 2007,
neither the Company nor anyone acting on its behalf consulted
Ernst & Young regarding (1) either the application
of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that might
be rendered on the Companys consolidated financial
statements or (2) any matter that was either the subject of
a disagreement with Rotenberg on accounting principles or
practices, financial statement disclosure, or auditing scope or
procedures, which, if not resolved to the satisfaction of
Rotenberg , would have caused Rotenberg LLP to make reference to
the matter in their report, or a reportable event as defined in
Item 304(a)(1)(v) of
Regulation S-K
of the Securities and Exchange Commission. On April 11,
2007, the Company provided a copy of the foregoing disclosure to
Ernst and Young LLP and provided Ernst and Young LLP with an
opportunity to furnish a letter addressed to the Securities and
Exchange Commission containing any new information,
clarification of the Companys expression of its views, or
the respects in which it does not agree with the statements made
by the Company. Ernst and Young LLP advised the Company that it
reviewed the foregoing disclosures and had no basis on which to
submit such a letter addressed to the Securities and Exchange
Commission in response to Item 304 of SEC
Regulation S-K.
Audit
Fees
Our principal accountants billed us an aggregate of $55,500 and
$29,000 in fees and expenses for professional services rendered
in connection with the audits of our financial statements for
the calendar years ended December 31, 2006 and 2005,
respectively, and reviews of the financial statements included
in our quarterly reports on
Form 10-Q
during such calendar years.
Audit
Related Fees
Our principal accountants billed us an aggregate of $11,000 and
$23,000 in audit related fees for due diligence for the calendar
years ended December 31, 2006 and 2005, respectively.
Tax
Fees
Our principal accountants billed us an aggregate of $4,000 and
$15,000 in fees and expenses for tax compliance, tax advice and
tax planning during calendar years ended December 31, 2006
and 2005, respectively.
All Other
Fees
Our principal accountants did not bill us any additional fees
that are not disclosed under audit fees, audit related fees or
tax fees in each of the last two calendar years.
Audit
Committee Policy for Pre-approval of Independent Auditor
Services
The audit committee of the board of directors is required to
pre-approve all audit and non-audit services provided by the
Companys independent auditors in order to assure that the
provision of such services does not impair the auditors
independence. The audit committee has established a policy
regarding pre-approval of permissible audit, audit-related and
other services provided by the independent auditors, which
services are periodically reviewed and revised by the audit
committee. Unless a type of service has received general
pre-approval under the policy, the service will require specific
approval by the audit committee. The policy also includes
14
pre-approved fee levels for specified services, and any proposed
service exceeding the established fee level must be specifically
approved by the Committee.
APPROVAL
OF THE COMPANYS 2007 EQUITY INCENTIVE PLAN
General
Effective upon April 25, 2007, we implemented the
Companys 2007 Equity Incentive Plan, which was approved by
our board of directors on April 25, 2007. The following
discussion is qualified in its entirety by the text of our 2007
Equity Incentive Plan which is included with this information
statement as Appendix A.
Awards
Awards granted under the 2007 Equity Incentive Plan may consist
of incentive stock options, non-qualified stock options, stock
appreciation rights (SAR), restricted stock grants, restricted
stock units (RSU) performance shares, performance units or cash
awards. Each award is subject to the terms and conditions set
forth in the 2007 Equity Incentive Plan and to those other terms
and conditions specified by the Committee and memorialized in a
written award agreement.
Shares Subject
to the 2007 Equity Incentive Plan
Subject to adjustment in certain circumstances as discussed
below, the 2007 Equity Incentive Plan authorizes up to
35,000,000 shares of our common stock for issuance pursuant
to the terms of the 2007 Equity Incentive Plan. If and to the
extent Awards granted under the 2007 Equity Incentive Plan
terminate, expire, cancel, or are forfeited without being
exercised and/or delivered, the shares subject to such awards
again will be available for grant under the 2007 Equity
Incentive Plan. Additionally, to the extent any shares subject
to an award are tendered and/or withheld in settlement of any
exercise price and/or any tax withholding obligation associated
with that award, those shares will again be available for grant
under the 2007 Equity Incentive Plan.
In the event of any recapitalization, reorganization, merger,
stock split or combination, stock dividend or other similar
event or transaction, substitutions or adjustments will be made
by our compensation committee to: (i) to the aggregate
number, class and/or issuer of the securities reserved for
issuance under the 2007 Equity Incentive Plan; (ii) to the
number, class and/or issuer of securities subject to outstanding
awards; and (iii) to the exercise price of outstanding
options or SARs, in each case in a manner that reflects
equitably the effects of such event or transaction.
Administration
The 2007 Equity Incentive Plan will be administered and
interpreted by our board of directors or by our compensation
committee. Our board of directors will have full authority to
grant awards under the 2007 Equity Incentive Plan and determine
the terms of such awards, including the persons to whom awards
are to be granted, the type and number of awards to be granted
and the number of shares of our common stock to be covered by
each award. Our board of directors will also have full authority
to specify the time(s) that which awards will be exercisable or
settled.
Eligibility
Employees, directors, consultants and other of our service
providers that provide services to us are eligible to
participate in the 2007 Equity Incentive Plan, provided,
however, that only employees of ours or our subsidiaries are
eligible to receive incentive stock options.
Per
Person Limitations
Maximum Aggregate Number of Shares Underlying
Stock-Based Awards Granted Under the 2007 Equity Incentive Plan
to any Single Participant. The
maximum aggregate number of shares of Common Stock underlying
all awards measured in shares of Common Stock (whether payable
in Common Stock, cash or a
15
combination of both) that may be granted to any single
participant in respect of any fiscal year of the Company shall
be 2,000,000 shares.
Maximum Dollar Amount Underlying Cash-Based Awards Granted
Under the 2007 Equity Incentive Plan to Any Single
Participant. The maximum dollar amount that
may be paid to any single participant with respect to all awards
measured in cash (whether payable in Common Stock, cash or a
combination of both) in respect of any fiscal year of the
Company shall be $2,000,000.
Stock
Options
General. Our compensation
committee may grant options qualifying as incentive stock
options (ISO) within the meaning of Section 422 of the Code
and/or Non-Qualified Stock Options (NQSO) in accordance with the
terms and conditions set forth in the 2007 Equity Incentive Plan.
Term, Purchase Price, Vesting and Method of Exercise of
Options. The exercise price of any stock
option granted under the 2007 Equity Incentive Plan will be the
fair market value of such stock on the date the option is
granted.
Our compensation committee may determine the option exercise
period for each option; provided, however, that the
exercise period of any option intended to be an ISO, may not
exceed ten (10) years from the date of grant. Vesting for
each option will also be determined by our compensation
committee.
Generally, payment of the option price may be made (i) in
cash, (ii) unless otherwise determined by our compensation
committee, in shares subject to the option via net-share
settlement whereby the cost to exercise the option is satisfied
by share withholding, (iii) by such other method as our
compensation committee may approve. The participant must pay the
option price and the amount of withholding tax due, if any, at
the time of exercise. Shares of our common stock will not be
issued or transferred upon exercise of the option until the
option price and the withholding obligation are fully paid.
SARs
Our compensation committee is authorized to grant SARs pursuant
to the terms of the 2007 Equity Incentive Plan. Upon exercise of
a SAR, the participant is entitled to receive an amount equal to
the difference between the fair market value of the shares of
our common stock underlying the SAR on the date of grant and the
fair market value of the shares of our common stock underlying
the SAR on the date of exercise. Such amount may be paid in cash
or shares of our common stock as determined by our compensation
committee.
Restricted
Stock Awards
Our compensation committee is authorized to grant awards of
restricted stock. Prior to the end of the restricted period,
shares received as restricted stock may not be sold or disposed
of by participants, and may be forfeited in the event of
termination of employment in certain circumstances. The
restricted period generally is established by our compensation
committee. While the shares remain unvested, a participant may
not sell, assign, transfer, pledge or otherwise dispose of the
shares. Unless otherwise determined by our compensation
committee, an award of restricted stock entitles the participant
to all of the rights of a stockholder, including the right to
vote the shares and the right to receive any dividends thereon.
RSUs
Our compensation committee is authorized to issue RSUs pursuant
to the terms of the 2007 Equity Incentive Plan. A RSU is a
contractual promise to issue shares and/or cash in an amount
equal to the fair market value (determined at the time of
distribution) of the shares of our common stock subject to the
award, at a specified future date, subject to the fulfillment of
vesting conditions specified by our compensation committee.
Prior to settlement, a RSU carries no voting or dividend rights
or other rights associated with stock ownership. A RSU award may
be settled in our common stock, cash, or in any combination of
our common stock and/or cash; provided, however, that a
determination to settle a RSU in whole or in part in cash shall
be made by our compensation committee, in its sole discretion.
16
Performance
Awards
In order to enable the Company to avail itself of the tax
deductibility of qualified performance-based
compensation, within the meaning of Code
Section 162(m), the 2007 Equity Incentive Plan provides for
performance based awards, the grant or vesting of which is
dependent upon attainment of objective performance targets
relative to certain performance measures. Our compensation
committee shall use the following performance measures (either
individually or in any combination) to set performance goals
with respect to awards intended to qualify as Performance-Based
Awards: net sales; pretax income before allocation of corporate
overhead and bonus; budget; cash flow; earnings per share; net
income; financial goals; return on shareholders equity;
return on assets; attainment of strategic and operational
initiatives; appreciation in and/or maintenance of the price of
the Common Stock or any other publicly-traded securities of the
Company; market share; gross profits; earnings before interest
and taxes; earnings before interest, taxes, depreciation and
amortization; economic value-added models; comparisons with
various stock market indices; and/or reductions in costs.
Amendment
and Termination of the 2007 Equity Incentive Plan
Our board of directors may amend, alter or discontinue the 2007
Equity Incentive Plan at any time, provided however, that
any amendment that increases the aggregate number of shares of
our common stock that may be issued or transferred under the
2007 Equity Incentive Plan, or changes the class of individuals
eligible to participate in the 2007 Equity Incentive Plan, will
be subject to approval by our stockholders. An ISO may not be
granted after the date, which is ten (10) years from the
effective date of the 2007 Equity Incentive Plan (or, if
stockholders approve an amendment that increases the number of
shares reserved for issuance under the 2007 Equity Incentive
Plan, ten (10) years from the date of the amendment).
Thereafter, the 2007 Equity Incentive Plan will remain in effect
for the purposes of awards other than ISOs, unless and until
otherwise determined by our board of directors.
Accelerated
Vesting Upon a Change in Control
Notwithstanding any other provision of the 2007 Equity Incentive
Plan to the contrary, and without limiting the powers of our
compensation committee under the 2007 Equity Incentive Plan, if
there is a Change in Control of the Company, as defined in the
2007 Equity Incentive Plan, the vesting date and/or payout of
each outstanding award shall be accelerated so that each such
award shall, immediately prior to the effective date of the
Change in Control, become fully vested with respect to the total
number of shares of common stock subject to such award. Upon the
consummation of any Change in Control, all outstanding awards
under the 2007 Equity Incentive Plan shall, to the extent not
previously exercised, either be assumed by any successor
corporation or parent thereof or be replaced with a comparable
award with respect to shares of common stock of such successor
corporation or parent thereof.
New Plan
Benefits
Because future awards under the 2007 Equity Incentive Plan will
be granted at the discretion of our compensation committee, the
type, number, recipients, and other terms of such awards cannot
be determined at this time. However, information regarding our
recent practices with respect to annual, long-term and
stock-based compensation under other plans is presented above in
the Summary Compensation Table and Grants of
Plan-Based Awards Table.
Federal
Income Tax Consequences under the 2007 Equity Incentive
Plan
Set forth below is a general description of the federal income
tax consequences relating to awards granted under the 2007
Equity Incentive Plan. Participants are urged to consult with
their personal tax advisors concerning the application of the
principles discussed below to their own situations and the
application of state and local tax laws.
NQSOs
There are no federal income tax consequences to participants or
to us upon the grant of a NQSO. Upon the exercise of a NQSO,
participants will recognize ordinary income in an amount equal
to the excess of the fair market value of the shares at the time
of exercise over the exercise price of the NQSO and we generally
will be entitled to a
17
corresponding federal income tax deduction at that time. Upon
the sale of shares acquired by exercise of a NQSO, a participant
will have a capital gain or loss (long-term or short-term
depending upon the length of time the shares were held) in an
amount equal to the difference between the amount realized upon
the sale and the participants adjusted tax basis in the
shares (the exercise price plus the amount of ordinary income
recognized by the participant at the time of exercise of the
NQSO).
ISOs
Participants will not be subject to federal income taxation upon
the grant or exercise of an ISO and we will not be entitled to a
federal income tax deduction by reason of such grant or
exercise. However, the amount by which the fair market value of
the shares at the time of exercise exceeds the option exercise
price is an item of tax preference subject to the alternative
minimum tax. A sale of shares acquired by exercise of an ISO
that does not occur within one year after the exercise or within
two years after the grant of the ISO generally will result in
the recognition of long-term capital gain or loss equal to the
difference between the amount realized on the sale and the
option exercise price and we will not be entitled to any tax
deduction in connection therewith.
If such sale occurs within one year from the date of exercise of
the ISO or within two years from the date of grant, also known
as a disqualifying disposition, the participant generally will
recognize ordinary income equal to the lesser of the excess of
the fair market value of the shares on the date of exercise over
the exercise price, or the excess of the amount realized on the
sale of the shares over the exercise price. We generally will be
entitled to a tax deduction on a disqualifying disposition
corresponding to the ordinary compensation income recognized by
the participant.
SARs
The participant will not recognize any income upon the grant of
a SAR. Upon the exercise of a SAR, the participant will
recognize ordinary compensation income equal to the value of the
shares of our common stock and/or cash received upon such
exercise, and we will be entitled to a corresponding deduction.
Shares received in connection with the exercise of a SAR will
have a tax basis equal to their fair market value on the date of
transfer, and the holding period of the shares will commence on
that date for purposes of determining whether a subsequent
disposition of the shares will result in long-term or short-term
capital gain or loss.
Restricted
Stock
A participant normally will not recognize taxable income upon
the award of restricted stock, and we will not be entitled to a
deduction, until such stock is transferable by the participant
or is no longer subject to a substantial risk of forfeiture for
federal tax purposes, whichever occurs earlier. When the shares
of common stock are either transferable or is no longer subject
to a substantial risk of forfeiture, the participant will
recognize ordinary compensation income in an amount equal to the
difference between the fair market value of the shares of common
stock subject to the award at that time and the amount paid by
the participant for the shares, if any. We will be entitled to a
deduction equal to the income recognized by the participant.
A participant may, however, elect to recognize ordinary income
in the year the restricted stock is granted in an amount equal
to the difference between the fair market value of the shares of
common stock subject to the award at that time, determined
without regard to any restrictions, and the amount paid by the
participant for the shares, if any. In this event, we will be
entitled to a deduction equal to the amount recognized as
compensation by the participant in the same year. In addition,
in this event, the participant will not be required to recognize
any taxable income upon vesting of the shares. Any gain or loss
recognized by the participant upon subsequent disposition of the
share of common stock will be capital gain or loss (long-term or
short-term, depending on how long the shares were held). If,
after making the election, any share of common stock subject to
an award is forfeited, the participant will not be entitled to
any tax deduction or tax refund.
RSUs
A participant will not recognize taxable income upon the grant
of a RSU, and we will not be entitled to a deduction, until the
shares and/or cash with respect to the award are transferred to
the participant, generally at the
18
end of the vesting period. At the time of transfer, the
participant will recognize ordinary income equal to the value of
the shares of common stock and/or cash. We will be entitled to a
deduction equal to the income recognized by the participant. The
subsequent disposition of shares acquired pursuant to a RSU
Award will result in capital gain or loss (based upon the
difference between the price received upon disposition and the
participants basis in those shares i.e.,
generally, the market value of the shares at the time of their
distribution).
Section 162(m)
Under the 2007 Equity Incentive Plan, options or SARs granted
with an exercise price at least equal to 100% of the fair market
value of the underlying shares at the date of grant and awards
that are conditioned upon achievement of certain performance
goals may satisfy the requirements for treatment as
qualified performance-based compensation. A number
of other requirements must be met, however, in order for those
awards to so qualify. Accordingly, there can be no assurance
that such awards under the 2007 Equity Incentive Plan will be
fully deductible under all circumstances. In addition, other
awards under the 2007 Equity Incentive Plan generally will not
so qualify, so that compensation paid to certain executives in
connection with those awards may, to the extent it and other
non-exempt compensation exceed $1,000,000 in any given year, be
subject to the deduction limitation of Section 162(m) of
the Code.
APPROVAL
TO CHANGE THE COMPANYS NAME TO OPKO HEALTH, INC.
The board of directors unanimously approved and recommended for
stockholder approval a change of the Companys name from
eXegenics Inc. to Opko Health, Inc. The affirmative vote of the
holders of a majority of outstanding shares of common stock and
preferred stock, voting as a single class, was obtained and will
be effective May , 2007.
The primary reason for the proposed name change was to better
clarify the identity of the Company after the Acquisition and to
reflect the Companys evolution towards becoming a leading
ophthalmology company.
To effectuate the change of the Companys name, we will
file the Companys Amended and Restated Articles of
Incorporation with the Secretary of State of the State of
Delaware, as described further below. After the filing of the
Amended and Restated Articles of Incorporation with the
Secretary of State of the State of Delaware, the Company shall
cease use of the name eXegenics Inc. The Company will use the
name Opko Health, Inc. and its subsidiaries will continue to use
the Acuity and Froptix names.
We anticipate filing the Amended and Restated Articles of
Incorporation approximately twenty (20) days after the
mailing of this information statement.
APPROVAL TO AMEND AND RESTATE OUR ARTICLES OF
INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED
SHARES OF COMMON STOCK FROM 225,000,000 TO 500,000,000.
The Companys current Articles of Incorporation provides
for an authorized capitalization consisting of
225,000,000 shares of common stock, $.001 par value per
share, and 10,000,000 shares of preferred stock, $.001 par
value per share. As of March 30, 2007, there were
113,116,350 shares of Common Stock outstanding and
97,958,843 shares reserved for issuance upon conversion of
outstanding options, warrants and shares of preferred stock.
The board of directors unanimously approved and recommended for
stockholder approval a proposal to amend and restate the
Companys Articles of Incorporation. The affirmative vote
of the holders of a majority of outstanding shares of common
stock and preferred stock, voting as a single class, was
obtained and will be effective May , 2007.
The primary reason for adopting the Amended and Restated
Articles of Incorporation is to increase the authorized number
of shares of the Companys common stock. The Amended and
Restated Articles of Incorporation provide for an increase in
the number of authorized shares of common stock to 500,000,000.
The increase in the authorized number of shares of common stock
will enable the Company to have sufficient authorized but
unissued capital stock for use in future equity financings and
to be reserved for issuance pursuant to our 2007 Equity
Incentive Plan, as described above. This increase in authorized
shares will empower our board of directors under
19
certain circumstances to issue the additional shares without
prior notice to our stockholders and without their approval.
We anticipate filing the Amended and Restated Articles of
Incorporation approximately twenty (20) days after the
mailing of this information statement.
ADDITIONAL
INFORMATION
Regulations regarding the delivery of copies of proxy materials
and annual reports to stockholders permit us, banks, brokerage
firms and other nominees to send one annual report and proxy
statement to multiple stockholders who share the same address
under certain circumstances. This practice is known as
householding. Stockholders who hold their shares
through a bank, broker or other nominee may have consented to
reducing the number of copies of materials delivered to their
address. In the event that a stockholder wishes to revoke a
household consent previously provided to a bank,
broker or other nominee, the stockholder must contact the bank,
broker or other nominee, as applicable, to revoke such consent.
In any event, if a stockholder wishes to receive a separate copy
of this information statement or future proxy statements and
annual reports, such stockholder should submit this request to
the Secretary of the Company, Adam Logal, at Opko Health, Inc.,
4400 Biscayne Boulevard, Suite 900, Miami, Florida 33137 by
mail or by calling
(305) 575-4148.
Any stockholders of record sharing an address who now receive
multiple copies of our annual reports and proxy statements and
who wish to receive only one copy of these materials per
household in the future should also contact the Secretary of the
Company by mail or telephone as instructed above. Any
stockholders sharing an address whose shares of common stock are
held by a bank, broker or other nominee who now receive multiple
copies of our annual reports and proxy statements, and who wish
to receive only one copy of these materials per household,
should contact the bank, broker or other nominee to request that
only one set of these materials be delivered in the future.
20
APPENDIX A
OPKO
HEALTH, INC.
2007
EQUITY INCENTIVE PLAN
1.
DEFINITIONS
The following terms shall have the following meanings unless the
context indicates otherwise:
1.1. Affiliate and
Associate shall have the respective
meanings given to such terms under
Rule 12b-2
under the Exchange Act.
1.2. Award shall mean either a Stock
Option, an SAR, a Stock Award, a Stock Unit, a Performance
Share, a Performance Unit, or a Cash Award.
1.3. Award Agreement shall mean a
written agreement between the Company and the Participant that
establishes the terms, conditions, restrictions and/or
limitations applicable to an Award in addition to those
established by the Plan and by the Committees exercise of
its administrative powers.
1.4. Beneficial Owner shall have the
meaning given to such term under
Rule 13d-3
under the Exchange Act.
1.5. Board shall mean the Board of
Directors of the Company.
1.6. Cash Award shall mean the grant
by the Committee to a Participant of an award of cash as
described in Section 11 below.
1.7. Cause shall mean (i) willful
malfeasance or willful misconduct by the Employee in connection
with his/her employment, (ii) continuing failure to perform
such duties as are requested by the Company and/or its
subsidiaries, (iii) failure by the Employee to observe
material policies of the Company and/or its subsidiaries
applicable to the Employee, (iv) material breach of any
agreement with or duty owed to the Company and/or its
subsidiaries applicable to the Employee, or (v) the
commission by the Employee of (x) any felony or
(y) any misdemeanor involving moral turpitude.
1.8. Change in Control of the Company
or Change in Control shall mean the
occurrence of any of the following events:
(a) any Person, as such term is used for purposes of
Section 13(d) or 14(d) of the Exchange Act, or any
successor section thereto, (other than (i) the Company,
(ii) any trustee or other fiduciary holding securities
under an employee benefit plan of the Company, (iii) any
Subsidiaries of the Company, (iv) any company owned,
directly or indirectly, by the shareholders of the Company in
substantially the same proportions as their ownership of stock
of the Company), or (v) the Frost Group, LLC or any of its
Affiliates becomes, either alone or together with such
Persons Affiliates and Associates, the Beneficial Owner,
directly or indirectly, of securities of the Company
representing 50% or more of the combined voting power of the
Companys then-outstanding securities.
(b) during any period of twenty-four months, individuals
who at the beginning of such period constitute the Board, and
any new directors whose election by the Board or nomination for
election by the Companys shareholders was approved by a
vote of at least two-thirds of the directors then still in
office who either were directors at the beginning of the period
or whose election or nomination for election was previously so
approved, cease for any reason to constitute at least a majority
thereof;
(c) the effective date or date of consummation of any
transaction or series of transactions (other than a transaction
to which only the Company and one or more of its subsidiaries
are parties) under which the Company is merged or consolidated
with any other company, other than a merger or consolidation
which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into
voting securities of the surviving entity) 50% or more of the
combined voting power of the voting securities of the Company or
such surviving entity outstanding immediately after such merger
or consolidation; or
A-1
(d) the shareholders of the Company approve a plan of
complete liquidation of the Company or an agreement for the sale
or disposition by the Company of all or substantially all of the
Companys assets.
1.9. Code shall mean the Internal
Revenue Code of 1986, as amended from time to time.
1.10. Committee shall mean the
Boards Compensation Committee or any other committee of
the Board appointed to administer this Plan.
1.11. Common Stock shall mean the
common stock of the Company.
1.12. Company shall mean Opko Health,
Inc., a Delaware Corporation.
1.13. Disability shall mean the
inability to engage in any substantial gainful activity by
reason of a medically determinable physical or mental impairment
which constitutes a permanent and total disability, as defined
in Section 22(e) (3) of the Code (or any successor
section thereto) and has applied for and been granted Long Term
Disability under the Companys Long Term Disability Plan.
The determination whether a Participant has suffered a
Disability shall be made by the Committee, in its sole
discretion, based upon such evidence as it deems necessary and
appropriate, and shall be conclusive and binding on the
Participant. A Participant shall not be considered disabled
unless he or she furnishes such medical or other evidence of the
existence of the Disability as the Committee, in its sole
discretion, may require.
1.14. Dividend Equivalent Right shall
mean the right to receive an amount equal to the amount of any
dividend paid with respect to a share of Common Stock multiplied
by the number of shares of Common Stock underlying or with
respect to a Stock Option, a SAR, a Stock Unit or a Performance
Unit, and which shall be payable in cash, in Common Stock, in
the form of Stock Units or Performance Units, or a combination
of any or all of the foregoing.
1.15. Effective Date shall mean the
date on which the Board adopts the Plan.
1.16. Employee shall mean an employee
of the Company or any Subsidiary as described in Treasury
Regulation Section 1.421-7(h).
1.17. Exchange Act shall mean the
Securities Exchange Act of 1934, as amended from time to time,
including applicable regulations thereunder.
1.18. Fair Market Value shall, unless
otherwise required by any applicable provision of the Code or
any Treasury Regulations, mean:
(a) if a security is listed or trading on a national
securities exchange or other market system, the closing price of
such security on the date of calculation (or on the last
preceding trading date if such security was not traded on such
date), or
(b) if such security is not listed or trading on a national
securities exchange or other market system, as determined in
good faith by the Board or the Committee.
1.19. Family Members shall mean a
Participants spouse, parents, children, and siblings,
whether by blood, marriage or adoption.
1.20. Independent Contractor shall
mean a Person (other than a Person who is an Employee or a
Nonemployee Director) or an entity that renders services to the
Company or any Subsidiary.
1.21. ISO shall mean an
incentive stock option as such term is used in Code
Section 422.
1.22. Nonemployee Director shall mean
a member of the Board or the board of directors of a Subsidiary
who is not an Employee.
1.23. Nonqualified Stock Option shall
mean a Stock Option that is not an ISO.
1.24. Participant shall mean any
Employee, Nonemployee Director or Independent Contractor to whom
an Award has been granted by the Committee under the Plan.
A-2
1.25. Performance-Based Award shall
mean an Award subject to the achievement of certain performance
goal or goals as described in Section 12 below.
1.26. Performance Share shall mean the
grant by the Committee to a Participant of an Award as described
in Section 10.1 below.
1.27. Performance Unit shall mean the
grant by the Committee to a Participant of an Award as described
in Section 10.2 below.
1.28. Person shall mean any person,
entity or group (within the meaning of
Section 13(d)(3) or Section 14(d)(2) of the Exchange
Act).
1.29. Plan shall mean the Opko Health,
Inc. 2007 Equity Incentive Plan, as it may be amended from time
to time.
1.30. Retirement shall mean the
termination of the employment, other than for Cause or due to
death or Disability, of a Participant who; (i) has reached
the age of 65; (ii) has reached the age of 62 and has
completed 5 years of service with the Company; or
(iii) has reached the age of 60 and has completed
10 years of service with the Company.
1.31. SAR shall mean the grant by the
Committee to a Participant of a stock appreciation right as
described in Section 8 below.
1.32. Stock Award shall mean the grant
by the Committee to a Participant of an Award of Common Stock as
described in Section 9.1 below.
1.33. Stock Option shall mean the
grant by the Committee to a Participant of an option to purchase
Common Stock as described in Section 7 below.
1.34. Stock Unit shall mean the grant
by the Committee to a Participant of an Award as described in
Section 9.2 below.
1.35. Subsidiary shall mean a
corporation of which the Company is the Beneficial Owner,
directly or indirectly, of more than 50% of the Voting Stock or
any other business entity in which the Company is the Beneficial
Owner, directly or indirectly, of more than 50% or any other
business venture designated by the Committee in which the
Company has a significant interest, as determined in the
discretion of the Committee.
1.36. Treasury Regulations shall mean
the regulations promulgated under the Code by the United States
Department of the Treasury, as amended from time to time.
1.37. Vest shall mean:
(a) with respect to Stock Options and SARs, when the Stock
Option or SAR (or a portion of such Stock Option or SAR) first
becomes exercisable and remains exercisable subject to the terms
and conditions of such Stock Option or SAR; or
(b) with respect to Awards other than Stock Options and
SARs, when the Participant has:
(i) an unrestricted right to receive the compensation
(whether payable in Common Stock, cash or a combination of both)
attributable to such Award (or a portion of such Award) or to
otherwise enjoy the benefits underlying such Award; and
(ii) a right to transfer an Award subject to no
Company-imposed restrictions or limitations other than
restrictions and/or limitations imposed by Section 14 below
1.38. Vesting Date shall mean the date
or dates on which an Award Vests.
1.39. Voting Stock shall mean the
capital stock of any class or classes having general voting
power under ordinary circumstances, in the absence of
contingencies, to elect the directors of a corporation.
A-3
2.
PURPOSE AND TERM OF PLAN
2.1. Purpose. The purpose of the Plan is to motivate
certain Employees, Nonemployee Directors and Independent
Contractors to put forth maximum efforts toward the growth,
profitability, and success of the Company and Subsidiaries by
providing incentives to such Employees, Nonemployee Directors
and Independent Contractors either through cash payments and/or
through the ownership and performance of the Common Stock. In
addition, the Plan is intended to provide incentives which will
help the Company attract and retain highly qualified individuals
as Employees and Nonemployee Directors and to assist in aligning
the interests of such Employees and Nonemployee Directors with
those of its shareholders.
2.2. Term. The Plan shall be effective as of the
Effective Date; provided, however, that the Plan shall be
approved by the shareholders of the Company at an annual meeting
or any special meeting of shareholders of the Company within
12 months before or after the Effective Date, and such
approval by the shareholders of the Company shall be a condition
to the right of each Participant to receive Awards hereunder.
Any Award granted under the Plan prior to the approval by the
shareholders of the Company shall be effective as of the date of
grant (unless the Committee specifies otherwise at the time of
grant), but no such Award may Vest, be paid out, or otherwise be
disposed of prior to such shareholder approval. If the
shareholders of the Company fail to approve the Plan in
accordance with this Section 2.2, any Award granted under
the Plan shall be automatically cancelled without payment of any
consideration to the recipient of such Award. The Plan shall
remain in effect for ten years or until earlier terminated by
the Board and no Award may be granted under the Plan on a date
that is more than ten years from the Effective Date; provided,
however, that in the event of Plan termination or expiration,
the provisions of the Plan shall remain in effect as to any
Awards which remain outstanding until all such Awards have been
satisfied or are terminated under the terms of this Plan or
under the applicable Award Agreement.
3.
ELIGIBILITY AND PARTICIPATION
3.1. Eligibility. All Employees, all Nonemployee
Directors and all Independent Contractors shall be eligible to
participate in the Plan and to receive Awards. An
individuals status as a member of the Committee will not
affect his eligibility to participate in the Plan.
3.2. Participation. Participants shall consist of such
Employees, Nonemployee Directors and Independent Contractors as
the Committee in its sole discretion designates to receive
Awards under the Plan. Subject to Section 7.1, an Award may
also be granted to an Employee, in connection with hiring,
retention or otherwise prior to the date the Employee first
performs services for the Company or any Subsidiary, provided
that such Awards shall not become Vested prior to the date the
Employee first performs such services. Designation of a
Participant in any year shall not require the Committee to
designate such Person to receive an Award in any other year or,
once designated, to receive the same type or amount of Award as
granted to the Participant in any other year. The Committee
shall consider such factors as it deems pertinent in selecting
Participants and in determining the type and amount of their
respective Awards.
4.
ADMINISTRATION
4.1. Responsibility. The Committee shall have the
responsibility, in its sole discretion, to control, operate,
manage and administer the Plan in accordance with its terms;
provided, however, that the Board may in any instance perform
any of the functions of the Committee hereunder.
4.2. Award Agreement. Each Award granted under the Plan
shall be evidenced by an Award Agreement which shall be signed
by the Company and the Participant; provided, however, that in
the event of any conflict between a provision of the Plan and
any provision of an Award Agreement, the provision of the Plan
shall prevail.
4.3. Authority of the Committee. The Committee shall have
all the discretionary authority that may be necessary or helpful
to enable it to discharge its responsibilities with respect to
the Plan, including but not limited to the following:
(a) to determine eligibility for participation in the Plan
and to select Participants;
(b) to determine eligibility for and the type and size of
an Award granted under the Plan;
A-4
(c) to make Awards in accordance with the terms of the Plan
and to determine the terms and conditions of each Award;
(d) to supply any omission, correct any defect, or
reconcile any inconsistency in the Plan in such manner and to
such extent as it shall deem appropriate in its sole discretion
to carry the same into effect;
(e) to issue administrative guidelines as an aid to
administer the Plan and make changes in such guidelines as it
from time to time deems proper;
(f) to make rules for carrying out and administering the
Plan and make changes in such rules as it from time to time
deems proper;
(g) to the extent permitted under the Plan, grant waivers
of Plan terms, conditions, restrictions, and limitations and to
vary the terms of Awards
(h) to take account of tax, securities law and other
regulatory requirements of foreign jurisdictions;
(i) to accelerate the Vesting of any Award when such action
or actions would be in the best interest of the Company;
(j) to grant Awards in replacement of Awards previously
granted under this Plan or any other executive compensation plan
of the Company; and
(k) to take any and all other actions it deems necessary or
advisable for the proper operation or administration of the Plan.
4.4. Action by the Committee. The Committee may act only
by a majority of its members. Any determination of the Committee
may be made, without a meeting, by a writing or writings signed
by all of the members of the Committee. In addition, the
Committee may authorize any one or more of its members or,
subject to Section 4.5 below, one or more agents to execute
and deliver documents on behalf of the Committee.
4.5. Delegation of Authority. To the extent permitted by
applicable law, the Committee may delegate to one or more of its
members, or to one or more officers of the Company, such
administrative duties as it may deem advisable; provided,
however, that any such delegation shall be in writing and,
provided, further, that the Committee may not delegate its
authority (a) to make Awards to Participants or
(b) under Sections 4.3 (a), (b), (c), (d), (e), (f),
(g), (h), (i) or (j) or Section 16 of the Plan.
Any action undertaken by any such member or agent in accordance
with the Committees delegation of authority shall have the
same force and effect as if undertaken directly by the
Committee, and any reference in the Plan to the Committee shall,
to the extent consistent with the terms and limitations of such
delegation, be deemed to include a reference to such members or
agents. In addition, the Committee, or any Person to whom it has
delegated duties under this Section 4.5, may employ one or
more Persons to render advice with respect to any responsibility
the Committee or such Person may have under the Plan. The
Committee may employ such legal or other counsel, consultants
and agents as it may deem desirable for the administration of
the Plan. Expenses incurred by the Committee in the engagement
of such counsel, consultant or agent shall be paid by the
Company, or the Subsidiary whose employees have benefited from
the Plan, as determined by the Committee. In the performance of
its functions, the Committee shall be entitled to rely upon
information, opinions, computations and advice furnished by the
Companys officers, any counsel, consultant or agent
retained by the Committee, and any other party the Committee
deems necessary, and no member of the Committee shall be liable
for any action taken or not taken in reliance upon any such
advice.
4.6. Determinations and Interpretations by the Committee.
All determinations and interpretations made by the Committee
shall be binding and conclusive on all Participants and their
heirs, successors, and legal representatives.
4.7. Liability. No member of the Board, no member of the
Committee and no Employee shall be liable for any act or failure
to act hereunder, except in circumstances involving his or her
willful misconduct, or for any act or failure to act hereunder
by any other member or Employee or by any agent to whom duties
in connection with the administration of the Plan have been
delegated.
A-5
4.8. Indemnification. The Company shall indemnify members
of the Board, members of the Committee and any agent of the
Committee who is an Employee, against any and all liabilities or
expenses to which they may be subjected (including, without
limitation, the reasonable fees and expenses of counsel) by
reason of any act or failure to act with respect to their duties
on behalf of the Plan, except in circumstances involving such
Persons willful misconduct.
5.
SHARES SUBJECT TO PLAN
5.1. Available Shares. Subject to the provisions of
Section 5.2 below, the aggregate number of shares of Common
Stock which shall be available for grants or payments of Awards
under the Plan during its term shall be 35,000,000 shares
(the Total Plan Shares). In the event
that (i) an Award (or portion thereof) lapses, expires or
is otherwise terminated without the issuance of the shares
subject to such Award or is settled by the delivery of
consideration other than shares, (ii) shares are tendered
to pay the exercise price of a Stock Option or other Award or
(iii) shares are withheld from any award to satisfy a
Participants tax withholding obligations or, if
applicable, to pay the exercise price of a Stock Option or other
Award, such shares shall again become available for grants or
Awards hereunder. Such shares of Common Stock available for
issuance under the Plan may be either authorized but unissued
shares, shares of issued stock held in the Companys
treasury, or both, at the discretion of the Company. Awards that
are payable only in cash are not subject to this
Section 5.1.
5.2. Adjustment to Shares. The existence of the Plan, the
Award Agreements and the Awards granted hereunder shall not
affect or restrict in any way the right or power of the Company
or the shareholders of the Company to make or authorize any
adjustment, recapitalization, reorganization or other change in
the Companys capital structure or its business, any merger
or consolidation of the Company, any issue of stock or of
options, warrants or rights to purchase stock or of bonds,
debentures, preferred or prior preference stocks whose rights
are superior to or affect the Common Stock or the rights thereof
or which are convertible into or exchangeable for Common Stock,
or the dissolution or liquidation of the Company, or any sale or
transfer of all or any part of its assets or business, or any
other corporate act or proceeding, whether of a similar
character or otherwise. If there is any change in the Common
Stock of the Company, through merger, consolidation,
reorganization, recapitalization, stock dividend, stock split,
reverse stock split,
split-up,
split-off, spin-off, combination of shares, exchange of shares,
dividend in kind or other like change in capital structure or
distribution to shareholders of the Company in the nature of a
liquidating distribution or a distribution pursuant to a plan of
dissolution, the Committee may, in its discretion, make a
proportionate adjustment to each outstanding Award that the
Committee considers appropriate so that thereafter each such
Award shall be with respect to or exercisable for such
securities, cash and/or other property as would have been
received in respect of the Common Stock subject to such Award
had such Award been paid, distributed or exercised in full
immediately prior to such change or distribution. In addition,
in the event of any such change or distribution, in order to
prevent dilution or enlargement of Participants rights
under the Plan, the Committee shall have the authority to
adjust, in an equitable manner as it deems appropriate, the
number and kind of shares that may be received in respect of any
Award, the number and kind of shares subject to outstanding
Awards, the exercise price applicable to outstanding Stock
Options, and the Fair Market Value of the Common Stock and other
value determinations applicable to outstanding Awards.
Appropriate adjustments may also be made by the Committee in the
terms of any Awards granted under the Plan to reflect such
changes or distributions and to modify any other terms of
outstanding Awards on an equitable basis, including
modifications of performance goals and changes in the length of
performance periods; provided, however, that with respect to
Performance-Based Awards, such modifications and/or changes do
not disqualify compensation attributable to such Awards as
performance-based compensation under Code
Section 162(m). In addition, the Committee is authorized to
make adjustments to the terms and conditions of, and the
criteria included in, Awards in recognition of unusual or
nonrecurring events affecting the Company or the financial
statements of the Company, or in response to changes in
applicable laws, regulations, or accounting principles. The
Committees determination of what, if any, adjustments
shall be made shall be final and binding on the Company and all
Participants.
5.3. No Repricing. Absent shareholder approval, neither
the Committee nor the Board shall have the authority, with or
without the consent of the affected holders of the Awards, to
reprice an Award after the date of its initial grant
with a lower exercise price in substitution for the original
exercise price. Adjustments in accordance with Section 5.2
above shall not be deemed repricings for purposes of
this Section 5.3. This Section 5.3 may not be
A-6
amended, altered or repealed by the Committee or the Board
without the approval of the shareholders of the Company.
6.
MAXIMUM INDIVIDUAL AWARDS
6.1. Maximum Aggregate Number of Shares Underlying
Stock-Based Awards Granted Under the Plan to Any Single
Participant. The maximum aggregate number of shares of
Common Stock underlying all Awards measured in shares of Common
Stock (whether payable in Common Stock, cash or a combination of
both) that may be granted to any single Participant in respect
of any fiscal year of the Company shall be
2,000,000 shares, subject to adjustment as provided in
Section 5.2 above.
6.2. Maximum Dollar Amount Underlying Cash-Based Awards
Granted Under the Plan to Any Single Participant. The
maximum dollar amount that may be paid to any single Participant
with respect to all Awards measured in cash (whether payable in
Common Stock, cash or a combination of both) in respect of any
fiscal year of the Company shall be $2,000,000.
7. STOCK
OPTIONS
7.1. In General. The Committee may, in its sole
discretion, grant Stock Options to Employees, Nonemployee
Directors and Independent Contractors on or after the Effective
Date, subject, in all cases to Section 2.2 of the Plan. The
Committee shall, in its sole discretion, determine the
Employees, the Nonemployee Directors and Independent Contractors
who will receive Stock Options and the number of shares of
Common Stock underlying each Stock Option. Each Stock Option
shall be subject to such terms and conditions consistent with
the Plan set forth in the applicable Award Agreement and such
other terms and conditions consistent with the Plan and the
applicable Award Agreement as the Committee may impose from time
to time. In addition, each Stock Option shall be subject to the
following terms and conditions set forth in Sections 7.2
through 7.8 below.
7.2. Exercise Price. The Committee shall specify the
exercise price of each Stock Option in the Award Agreement;
provided, however, that the exercise price of any Nonqualified
Stock Option shall not be less than 100% of the Fair Market
Value of the Common Stock on the date of grant.
7.3. Term of Stock Option. The Committee shall specify
the term of each Stock Option in the Award Agreement shall
terminate as set forth in Section 14 below or at such
earlier times and upon such conditions or circumstances as the
Committee shall, in its sole discretion, set forth in the Award
Agreement.
7.4. Vesting Date. The Committee shall specify the
Vesting Date with respect to each Stock Option in the Award
Agreement; provided, that the Committee may provide in the
applicable Award Agreement that any Stock Option shall Vest in
such portions or installments as the Committee may, in its sole
discretion, determine. The Committee may grant Stock Options
that are Vested, either in whole or in part, on the date of
grant. If the Committee fails to specify a Vesting Date in the
Award Agreement, 25% of such Stock Option shall become
exercisable on each of the first four anniversaries of the date
of grant and shall remain exercisable following such anniversary
date until the Stock Option expires in accordance with its terms
under the Award Agreement or under the terms of the Plan. The
Vesting of a Stock Option may be subject to such other terms and
conditions as shall be determined by the Committee, including,
without limitation, accelerating the Vesting if certain
performance goals are achieved.
7.5. Exercise of Stock Options. The Stock Option exercise
price may be paid in cash or, in the sole discretion of the
Committee, by the delivery of shares of Common Stock or other
securities of the Company then owned by the Participant, by the
withholding of shares of Common Stock for which a Stock Option
is exercisable, or by a combination of these methods. In the
sole discretion of the Committee, and subject to all applicable
laws, rules and regulations, payment may also be made by
delivering a properly executed exercise notice to the Company
together with a copy of irrevocable instructions to a broker to
deliver promptly to the Company the amount of sale proceeds to
pay the exercise price. To facilitate the foregoing, the Company
may enter into agreements for coordinated procedures with one or
more brokerage firms. The Committee may prescribe any other
method of paying the exercise price that it determines to be
consistent with applicable law and the purpose of the Plan,
including, without limitation, in lieu of the exercise of a
Stock Option by delivery of shares of Common Stock then owned by
a Participant, providing the Company with a notarized statement
attesting to the number of shares owned by the
A-7
Participant, where upon verification by the Company, the Company
would issue to the Participant only the number of incremental
shares to which the Participant is entitled upon exercise of the
Stock Option. In determining which methods a Participant may
utilize to pay the exercise price, the Committee may consider
such factors as it determines are appropriate; provided,
however, that any method approved by the Committee shall comply
with applicable securities laws. When payment of the exercise
price for a Stock Option consists of shares of the
Companys capital stock or other securities of the Company,
such securities will not be accepted as payment unless the
Participant has held such shares for the requisite period
necessary to avoid a charge to the Companys earnings for
financial reporting purposes.
7.6. Additional Terms and Conditions. The Committee may,
by way of the Award Agreements or otherwise, establish such
other terms, conditions, restrictions and/or limitations, if
any, of any Stock Option, as they may determine in their sole
discretion; provided, they are not inconsistent with the Plan,
including, without limitation, any requirement that the
Participant not engage in competition with the Company or any
Subsidiary.
7.7. Conversion Stock Options. The Committee may, in its
sole discretion and upon such terms and conditions as it deems
appropriate, grant a Stock Option to any holder of an option
(hereinafter referred to as an Original Option) to
purchase shares of the stock of any corporation:
(a) the stock or all or substantially all of the assets of
which were acquired, directly or indirectly, by the Company or
any Subsidiary, or
(b) which was merged with and into the Company or a
Subsidiary, so that the Original Option is converted into a
Stock Option (hereinafter referred to as a Conversion
Stock Option); provided, however, that such Conversion
Stock Option as of the date of its grant (the
Conversion Stock Option Grant Date)
shall have substantially the same economic value as the Original
Option as of the Conversion Stock Option Grant Date.
8. STOCK
APPRECIATION RIGHTS
8.1. In General. The Committee may, in its sole
discretion, grant SARs to Employees, Nonemployee Directors,
and/or Independent Contractors. An SAR is a right to receive a
payment in cash, Common Stock or a combination of both, in an
amount equal to the excess of (x) the Fair Market Value of
the Common Stock, or other specified valuation, of a specified
number of shares of Common Stock on the date the SAR is
exercised over (y) the Fair Market Value of the Common
Stock, or other specified valuation (which shall be no less than
the Fair Market Value of the Common Stock), of such shares of
Common Stock on the date the SAR is granted, all as determined
by the Committee. If a SAR is granted retroactively in tandem
with or in substitution for a Stock Option, the designated Fair
Market Value of the Common Stock in the Award Agreement sall be
the Fair Market Value of the Common Stock on the date such Stock
Option was granted, the SAR shall cover the same number of
shares of Common Stock as covered by the Stock Option (or such
lesser number of shares as the Committee may determine) and the
SAR shall be exercisable only at such time or times and to the
extent the related Stock Option shall be exercisable, and shall
have the same term and exercise price as the related Stock
Option. Upon exercise of a Stock Appreciation Right granted in
tandem with a Stock Option, the related Stock Option shall be
cancelled automatically to the extent of the number of shares
covered by such exercise; conversely, if the related Stock
Option is exercised as to some or all of the shares covered by
the tandem grant, the tandem Stock Appreciation Right shall be
cancelled automatically to the extent of the number of shares
covered by the Stock Option exercised. Each SAR shall be subject
to such terms and conditions, including, but not limited to, a
provision that automatically converts a SAR into a Stock Option
on a conversion date specified at the time of grant, as the
Committee shall impose from time to time in its sole discretion
and subject to the terms of the Plan.
9. STOCK
AWARDS AND STOCK UNITS
9.1. Stock Awards. The Committee may, in its sole
discretion, grant Stock Awards to Employees, Nonemployee
Directors, and/or Independent Contractors as additional
compensation or in lieu of other compensation for services to
the Company. A Stock Award shall consist of shares of Common
Stock which shall be subject to such terms and conditions as the
Committee in its sole discretion determines appropriate,
including, without limitation, restrictions on the sale or other
disposition of such shares, the Vesting Date with respect to
such shares, and the right
A-8
of the Company to reacquire such shares for no consideration
upon termination of the Participants employment within
specified periods. With respect to the shares of Common Stock
subject to a Stock Award, the Participant shall have all of the
rights of a holder of shares of Common Stock, including the
right to receive dividends and to vote the shares, unless the
Committee determines otherwise on the date of grant. The
Committee may require the Participant to deliver a duly signed
stock power, endorsed in blank, relating to the Common Stock
covered by such Stock Award. As a condition to any Stock Award,
the Participant may be required to deliver to the Company a
share power, endorsed in blank, relating to the Shares covered
by such Award. Any share certificate issued in connection with a
Stock Award may be held in the custody of the Company and will
bear the following legend and/or any other legend required by
this Plan, the applicable Award Agreement or applicable law:
THE TRANSFERABILITY OF THIS CERTIFICATE AND THE
SHARES REPRESENTED HEREBY ARE SUBJECT TO THE TERMS AND
CONDITIONS OF THE OPKO HEALTH, INC. 2007 EQUITY INCENTIVE PLAN
AND AN AGREEMENT ENTERED INTO BETWEEN THE PARTICIPANT AND OPKO
HEALTH, INC. (WHICH TERMS AND CONDITIONS MAY INCLUDE, WITHOUT
LIMITATION, CERTAIN TRANSFER RESTRICTIONS AND FORFEITURE
CONDITIONS). COPIES OF THAT PLAN AND AGREEMENT ARE ON FILE IN
THE PRINCIPAL OFFICES OF EXEGENICS INC. AND WILL BE MADE
AVAILABLE TO THE HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON
REQUEST TO THE SECRETARY OF OPKO HEALTH, INC.
9.2. Stock Units. The Committee may, in its sole
discretion, grant Stock Units to Employees, Nonemployee
Directors, and/or Independent Contractors as additional
compensation or in lieu of other compensation for services to
the Company. A Stock Unit is a hypothetical share of Common
Stock represented by a notional account established and
maintained (or caused to be established or maintained) by the
Company for such Participant who receives a grant of Stock
Units. Stock Units shall be subject to such terms and conditions
as the Committee, in its sole discretion, determines appropriate
including, without limitation, determinations of the Vesting
Date with respect to such Stock Units and the criteria for the
Vesting of such Stock Units. A Stock Unit granted by the
Committee shall provide for payment in shares of Common Stock at
such time or times as the Award Agreement shall specify. The
Committee shall determine whether a Participant who has been
granted a Stock Unit shall also be entitled to a Dividend
Equivalent Right.
9.3. Payout of Stock Units. Subject to a
Participants election to defer in accordance with
Section 17.3 below, upon the Vesting of a Stock Unit, the
shares of Common Stock representing the Stock Unit shall be
distributed to the Participant, unless the Committee, in its
sole discretion, provides for the payment of the Stock Unit in
cash (or partly in cash and partly in shares of Common Stock)
equal to the value of the shares of Common Stock which would
otherwise be distributed to the Participant.
10.
PERFORMANCE SHARES AND PERFORMANCE UNITS
10.1. Performance Shares. The Committee may, in its sole
discretion, grant Performance Shares to Employees, Nonemployee
Directors, and/or Independent Contractors as additional
compensation or in lieu of other compensation for services to
the Company. A Performance Share shall consist of a share or
shares of Common Stock which shall be subject to such terms and
conditions as the Committee, in its sole discretion, determines
appropriate, including, without limitation, determining the
performance goal or goals which, depending on the extent to
which such goals are met, will determine the number and/or value
of the Performance Shares that will be paid out or distributed
to the Participant who has been granted Performance Shares.
Performance goals may be based on, without limitation,
Company-wide, divisional and/or individual performance, as the
Committee, in its sole discretion, may determine, and may be
based on the performance measures listed in Section 12.3
below. With respect to the Performance Shares, the Participant
shall have none of the rights of a holder of shares of Common
Stock, including the right to receive dividends and to vote the
shares, unless and until such Performance Shares shall have been
Vested and distributed to the Participant.
10.2. Performance Units. The Committee may, in its sole
discretion, grant Performance Units to Employees, Nonemployee
Directors, and/or Independent Contractors as additional
compensation or in lieu of other compensation for services to
the Company. A Performance Unit is a hypothetical share or
shares of Common Stock represented by a notional account which
shall be established and maintained (or caused to be established
or
A-9
maintained) by the Company for such Participant who receives a
grant of Performance Units. Performance Units shall be subject
to such terms and conditions as the Committee, in its sole
discretion, determines appropriate, including, without
limitation, determining the performance goal or goals which,
depending on the extent to which such goals are met, will
determine the number and/or value of the Performance Units that
will be accrued with respect to the Participant who has been
granted Performance Units. Performance goals may be based on,
without limitation, Company-wide, divisional and/or individual
performance, as the Committee, in its sole discretion, may
determine, and may be based on the performance measures listed
in Section 12.3 below.
10.3. Payout of Performance Shares or Performance Units.
Subject to a Participants election to defer in accordance
with Section 17.3 below, upon the Vesting of a Performance
Share or a Performance Unit, the shares of Common Stock
representing the Performance Share or the Performance Unit shall
be distributed to the Participant, unless the Committee, in its
sole discretion, provides for the payment of the Performance
Share or a Performance Unit in cash (or partly in cash and
partly in shares of Common Stock) equal to the value of the
shares of Common Stock which would otherwise be distributed to
the Participant.
11. CASH
AWARDS
11.1. In General. The Committee may, in its sole
discretion, grant Cash Awards to Employees, Nonemployee
Directors, and/or Independent Contractors as additional
compensation or in lieu of other compensation for services to
the Company. A Cash Award shall be subject to such terms and
conditions as the Committee, in its sole discretion, determines
appropriate, including, without limitation, determining the
Vesting Date with respect to such Cash Award, the criteria for
the Vesting of such Cash Award, and the right of the Company to
require the Participant to repay the Cash Award (with or without
interest) upon termination of the Participants employment
within specified periods.
12.
PERFORMANCE-BASED AWARDS
12.1. In General. The Committee, in its sole discretion,
may designate Awards granted under the Plan as Performance-Based
Awards (as defined below) if it determines that such
compensation might not be tax deductible by the Company due to
the deduction limitation imposed by Code Section 162(m).
Accordingly, an Award granted under the Plan may be granted in
such a manner that the compensation attributable to such Award
is intended by the Committee to qualify as qualified
performance-based compensation (as such term is used in
Code Section 162(m) and the Treasury Regulations
thereunder) and thus be exempt from the deduction limitation
imposed by Code Section 162(m) (Performance-Based
Awards).
12.2. Qualification of Performance-Based Awards. Awards
shall only qualify as Performance-Based Awards under the Plan if:
(a) at the time of grant the Committee is comprised solely
of two or more outside directors (as such term is
used in Code Section 162(m) and the Treasury Regulations
thereunder);
(b) with respect to either the granting or Vesting of an
Award (other than (i) a Nonqualified Stock Option or
(ii) a SAR, which are granted with an exercise price at or
above the Fair Market Value of the Common Stock on the date of
grant), such Award is subject to the achievement of a
performance goal or goals based on one or more of the
performance measures specified in Section 12.3 below;
(c) the Committee establishes in writing (i) the
objective performance-based goals applicable to a given
performance period and (ii) the individual employees or
class of employees to which such performance-based goals apply
no later than 90 days after the commencement of such
performance period (but in no event after 25 percent of
such performance period has elapsed);
(d) no compensation attributable to a Performance-Based
Award will be paid to or otherwise received by a Participant
until the Committee certifies in writing that the performance
goal or goals (and any other material terms) applicable to such
performance period have been satisfied; and
(e) after the establishment of a performance goal, the
Committee shall not revise such performance goal (unless such
revision will not disqualify compensation attributable to the
Award as performance-based
A-10
compensation under Code Section 162(m)) or increase
the amount of compensation payable with respect to such Award
upon the attainment of such performance goal.
12.3. Performance Measures. The Committee shall use the
following performance measures (either individually or in any
combination) to set performance goals with respect to Awards
intended to qualify as Performance-Based Awards: net sales;
pretax income before allocation of corporate overhead and bonus;
budget; cash flow; earnings per share; net income; financial
goals; return on shareholders equity; return on assets;
attainment of strategic and operational initiatives;
appreciation in and/or maintenance of the price of the Common
Stock or any other publicly-traded securities of the Company;
market share; gross profits; earnings before interest and taxes;
earnings before interest, taxes, depreciation and amortization;
economic value-added models; comparisons with various stock
market indices; and/or reductions in costs.
13.
CHANGE IN CONTROL
13.1. Accelerated Vesting. Notwithstanding any other
provision of this Plan to the contrary, and without limiting the
powers of the Committee under Section 4.3 of the Plan, if
there is a Change in Control of the Company, the Vesting Date
and/or payout of each outstanding Award shall be accelerated so
that each such Award shall, immediately prior to the effective
date of the Change in Control, become fully vested with respect
to the total number of shares of Common stock subject to such
Award. Upon the consummation of any Change of Control, all
outstanding Awards under the Plan shall, to the extent not
previously exercised, either be assumed by any successor
corporation or parent thereof or be replaced with a comparable
Award with respect to shares of common stock of such successor
corporation or parent thereof.
13.2. Cashout. The Committee, in its sole discretion, may
determine that, upon the occurrence of a Change in Control of
the Company, all or a portion of certain outstanding Awards
shall terminate within a specified number of days after notice
to the holders, and each such holder shall receive an amount
equal to the value of such Award on the date of the Change in
Control, and with respect to each share of Common Stock subject
to a Stock Option or SAR, an amount equal to the excess of the
Fair Market Value of such shares of Common Stock immediately
prior to the occurrence of such Change in Control (or such other
greater amount as the Committee may determine in its sole and
absolute discretion to be equitable to prevent dilution or
enlargement of Participants rights under the Plan) over
the exercise price per share of such Stock Option or SAR. Such
amount shall be payable in cash, in one or more kinds of
property (including the property, if any, payable in the
transaction) or in a combination thereof, as the Committee, in
its sole discretion, shall determine.
13.3. Assumption or Substitution of Awards.
Notwithstanding anything contained in the Plan to the contrary,
the Committee may, in its sole discretion, provide that an Award
may be assumed by any entity which acquires control of the
Company or may be substituted by a similar award under such
entitys compensation plans.
14.
TERMINATION OF EMPLOYMENT IF PARTICIPANT IS AN
EMPLOYEE
14.1. Termination of Employment Due to Death. Subject to
the terms of the Plan, any written agreement between the
Participant and the Company, and the applicable Award Agreement,
if a Participants employment is terminated due to death:
(a) all non-Vested portions of Awards held by the
Participant on the date of the Participants death shall
immediately be forfeited by such Participant as of such date; and
(b) all Vested portions of Stock Options and SARs held by
the Participant on the date of the Participants death
shall remain exercisable until the earlier of:
(i) the end of the
12-month
period following the date of the Participants death, or
(ii) the date the Stock Option or SAR would otherwise
expire.
14.2. Termination of Employment for Cause. Subject to the
terms of the Plan, any written agreement between the Participant
and the Company, and the applicable Award Agreement, if a
Participants employment is terminated by the Company for
Cause, all Awards held by a Participant on the date of the
termination of his or her employment for Cause, whether Vested
or non-Vested, shall immediately be forfeited by such
Participant as of such
A-11
date. If a Participants employment is terminated for Cause
during the six months following any exercise, payment or
delivery pursuant to an Award, such exercise, payment or
delivery may be rescinded within two years thereafter. In the
event of any such rescission, the Participant shall pay to the
Company the amount of any gain realized or payment received as a
result of the rescinded exercise, payment or delivery, in such
manner and on such terms and conditions as may be required, and
the Company shall be entitled to set-off against the amount of
any such gain any amount owed to the Participant by the Company.
14.3. Termination of Employment Due to Retirement or
Disability. Subject to the terms of the Plan, any written
agreement between the Participant and the Company, and the
applicable Award Agreement, if a Participants employment
is terminated due to Retirement or Disability of the Participant:
(a) all non-Vested portions of Awards held by the
Participant on the date of the Participants Retirement or
the date of the termination of his or her employment, as the
case may be, shall immediately be forfeited by such Participant
as of such date; and
(b) all Vested portions of Stock Options and SARs held by
the Participant on the date of the Participants Retirement
or the date of the termination of his or her employment, as the
case may be, shall remain exercisable until the earlier of:
(i) the end of the
36-month
period following the date of the Participants Retirement
or the date of the termination of his or her employment, as the
case may be, or
(ii) the date the Stock Option or SAR would otherwise
expire.
14.4. Other Terminations of Employment. Subject to the
terms of the Plan, any written agreement between the Participant
and the Company, and the applicable Award Agreement, if a
Participants employment is terminated for any reason other
than for Cause, retirement or due to death or Disability:
(a) all non-Vested portions of Awards held by the
Participant on the date of the termination of his or her
employment shall immediately be forfeited by such Participant as
of such date; and all Vested portions of Stock Options and/or
SARs held by the Participant on the date of the termination of
his or her employment shall remain exercisable until the earlier
of;
(i) the end of the
12-month
period following the date of the termination of the
Participants employment, or
(ii) the date the Stock Option or SAR would otherwise
expire.
14.5. Change in Status. Notwithstanding anything to the
contrary set forth in the Plan, if any Employee ceases for any
reason to be an Employee but continues to perform services for
the Company (whether as a Nonemployee Director, consultant,
agent, Independent Contractor or otherwise), such Participant
shall retain his or her Awards upon the original terms and
conditions thereof; provided, however, that if such Participant
thereafter ceases to perform services for the Company then the
provisions of this Section 14.4 shall no longer apply and
such Award shall thereafter be subject to the provisions of
Section 14.1, 14.2 or 14.3, as applicable.
14.6. Committee Discretion. Notwithstanding anything
contained in the Plan to the contrary, and without limiting the
powers of the Committee under Section 4.3 of the Plan, the
Committee may, in its sole discretion, provide that:
(a) any or all non-Vested portions of Stock Options and/or
SARs held by the Participant on the date of the
Participants death and/or the date of the termination of
his or her employment shall immediately become exercisable as of
such date and shall remain exercisable until a date that occurs
on or prior to the date the Stock Option or SAR is scheduled to
expire;
(b) any or all Vested portions of Nonqualified Stock
Options and/or SARs held by the Participant on the date of the
Participants death and/or the date of the termination of
his or her employment shall remain exercisable until a date that
occurs on or prior to the date the Stock Option or SAR is
scheduled to expire; and/or
A-12
(c) any or all non-Vested portions of Stock Awards, Stock
Units, Performance Shares, Performance Units, and/or Cash Awards
held by the Participant on the date of the Participants
death and/or the date of the termination of his or her
employment shall immediately Vest or shall become Vested on a
date that occurs on or prior to the date the Award is scheduled
to vest.
(d) Cancellation and Rescission of Awards Due to
Detrimental Activity. Unless the Award Agreement specifies
otherwise, and regardless of whether the Participants
employment or engagement with the Company is terminated (whether
for Cause or otherwise), the Committee may cancel, rescind, or
otherwise withhold any Awards held by a Participant, whether
Vested or non-Vested, and any such Awards shall immediately be
forfeited by such Participant at any time that the Participant
is not in compliance with all applicable provisions of the Award
Agreement and the Plan, or if the Participant engages in any
Detrimental Activity. For purposes of this
Section 14.6, Detrimental Activity shall
include: (i) the rendering of services, directly or
indirectly, to or for the benefit of any organization or
engaging directly or indirectly in any business which is
competitive with the Company, or which organization or business,
or the rendering of services to or for the benefit of such
organization, is prejudicial to or in conflict with the
interests of the Company; (ii) the disclosure to anyone
outside the Company, or the use in other than the Companys
business, without prior written authorization from the Company,
of any confidential information, as defined in the
Companys Employee Handbook, acquired by the Participant
either during or after employment with the Company;
(iii) the failure or refusal to disclose promptly and to
assign exclusively to the Company, all right title and interest
in any invention or idea, patentable or not, made or conceived
by the Participant during employment with the Company, relating
in any manner to the actual or anticipated business, research or
development work of the Company or the failure or refusal to do
anything reasonably necessary to enable the Company to secure a
patent where appropriate in the United States and in other
countries; (iv) a violation of any rule, policy, procedure
or guideline of the Company, including but not limited to the
Companys Code of Conduct; (v) any attempt, directly
or indirectly, to induce any employee of the Company to be
employed or render services other than for the Company, or any
attempt directly or indirectly to solicit the trade or business
of any current or prospective customer, supplier, or partner of
the Company, other than in connection with the Companys
business; (vi) the Participant being convicted of, or
entering a guilty plea with respect to a crime, whether or not
connected with the Company; (vii) any other conduct or act
determined to be injurious, detrimental or prejudicial to any
interest of the Company or (viii) any agreement, whether or
not in writing, to do any of the foregoing. Upon exercise,
payment or delivery pursuant to an Award, the Participant may be
required to certify, in a manner acceptable to the Committee,
that he or she is in compliance with all of the terms and
conditions of the Plan and is not and has not engaged in any
Detrimental Activity. In the event a Participant fails to comply
with the provisions of this Section 14.6 after the grant of
the Award and prior to, or during the six months after any
exercise, payment or delivery pursuant to an Award, such
exercise, payment or delivery may be rescinded within two years
thereafter. In the event of any such rescission, the Participant
shall pay to the Company the amount of any gain realized or
payment received as a result of the rescinded exercise, payment
or delivery, in such manner and on such terms and conditions as
may be required, and the Company shall be entitled to set-off
against the amount of any such gain any amount owed to the
Participant by the Company.
15.
TAXES
15.1. Withholding Taxes. With respect to Employees, the
Company, or the applicable Subsidiary, may require a Participant
whose Stock Award, Stock Unit, Performance Share or Performance
Unit granted hereunder has Vested, or who exercises a Stock
Option or SAR granted hereunder to reimburse the Company or the
Subsidiary which employs such Participant for any taxes required
by any governmental regulatory authority to be withheld or
otherwise deducted and paid by such corporation or entity in
respect of the issuance or disposition of such shares or the
payment of any amounts. In lieu thereof, the Company or the
Subsidiary which employs such Participant, shall have the right
to withhold the amount of such taxes from any other sums due or
to become due from the Company or the Subsidiary, as applicable,
to the Participant upon such terms and conditions as the
Committee shall in its sole discretion prescribe. The Company or
the Subsidiary that employs such Participant may, in its
discretion, hold the stock certificate to which such Participant
is entitled upon the Vesting of a Stock Award, Stock Unit,
Performance Share or Performance Unit or the exercise of a Stock
Option or SAR as security for the payment of such withholding
A-13
tax liability, until cash sufficient to pay that liability has
been accumulated by or paid to the Company or such Subsidiary.
15.2. Use of Common Stock to Satisfy Withholding
Obligation. With respect to Employees, at any time that the
Company, Subsidiary or other entity that employs such
Participant becomes subject to a withholding obligation under
applicable law with respect to the vesting of a Stock Award,
Stock Unit, Performance Share or Performance Unit or the
exercise of a Nonqualified Stock Option (the Tax
Date), except as set forth below, a holder of such Award
may, subject to the approval of the Committee, elect to satisfy,
in whole or in part, the holders related personal tax
liabilities (an Election) by (i) directing the
Company, Subsidiary or other entity that employs such
Participant to withhold from shares issuable in the related
vesting or exercise either a specified number of shares or
shares of Common Stock having a specified value (in each case
equal to the related minimum statutory personal withholding tax
liabilities with respect to the applicable taxing jurisdiction
in order to comply with the requirements for a fixed
plan under Accounting Principals Board Opinion
No. 25), (ii) tendering shares of Common Stock or
other securities of the Company previously issued pursuant to
the exercise of a Stock Option or other shares of the Common
Stock owned by the holder, or (iii) combining any or all of
the foregoing Elections in any fashion. The foregoing
notwithstanding, however, when previously issued shares of
Common Stock or other securities of the Company are tendered
pursuant to an Election, such tender of shares will not be
accepted unless the Participant has held such shares for the
requisite period necessary to avoid a charge to the
Companys earnings for financial reporting purposes. An
Election shall be irrevocable. The withheld shares and other
shares of Common Stock or other securities tendered in payment
shall be valued at their Fair Market Value on the Tax Date. The
Committee may in its sole discretion disapprove of any Election,
suspend or terminate the right to make Elections or provide that
the right to make Elections shall not apply to particular shares
or exercises. The Committee may impose any additional conditions
or restrictions on the right to make an Election as it shall
deem appropriate, including conditions or restrictions with
respect to Section 16 of the Exchange Act.
15.3. No Guarantee of Tax Consequences. No Person
connected with the Plan in any capacity, including, but not
limited to, the Company and any Subsidiary and their respective
directors, officers, agents and employees makes any
representation, commitment, or guarantee that any tax treatment,
including, but not limited to, federal, state and local income,
estate and gift tax treatment, will be applicable with respect
to amounts deferred under the Plan, or paid to or for the
benefit of a Participant under the Plan, or that such tax
treatment will apply to or be available to a Participant on
account of participation in the Plan.
16.
AMENDMENT AND TERMINATION
16.1. Termination of Plan. The Board or the Committee may
suspend or terminate the Plan at any time with or without prior
notice; provided, however, that no action authorized by this
Section 16.1 shall reduce the amount of any outstanding
Award or adversely change the terms and conditions thereof
without the Participants consent.
16.2. Amendment of Plan. Provided that no amendment may
adversely affect the rights of any Participant under any
outstanding Award without the Participants consent; and,
provided further, that no such amendment shall be effective
without shareholder approval if such approval is required to
comply with any applicable law or the rules of any national
securities exchange or other market system on which the
Companys securities are then listed or traded; and,
provided further, that the Board or the Committee may not,
without shareholder approval, increase the maximum number of
shares issuable under the Plan, the Board or the Committee may
amend the Plan at any time with or without prior notice.
Notwithstanding any provision herein to the contrary, the Board
or the Committee shall have broad authority to amend the Plan or
any Award to take into account changes in applicable tax laws,
securities laws, accounting rules and other applicable state and
federal laws.
16.3. Amendment or Cancellation of Award Agreements.
Without limitation to the rights of the Committee under
Sections 4.3 and 14.6 of the Plan, the Committee may amend
or modify any Award Agreement at any time by mutual agreement
between the Committee and the Participant or such other Persons
as may then have an interest therein. In addition, by mutual
agreement between the Committee and a Participant or such other
Persons as may then have an interest therein, Awards may be
granted to an Employee, Nonemployee Director or Independent
Contractor in substitution and exchange for, and in cancellation
of, any Awards previously granted to such Employee, Nonemployee
Director or Independent Contractor under the Plan, or any award
previously granted to
A-14
such Employee, Nonemployee Director or Independent Contractor
under any other present or future plan of the Company or any
present or future plan of an entity which (i) is purchased
by the Company, (ii) purchases the Company, or
(iii) merges into or with the Company.
17.
MISCELLANEOUS
17.1. Other Provisions. Awards granted under the Plan may
also be subject to such other provisions (whether or not
applicable to the Award granted to any other Participant) as the
Committee determines in its sole discretion on the date of grant
to be appropriate, including, without limitation, for the
installment purchase of Common Stock under Stock Options, to
assist the Participant in financing the acquisition of Common
Stock, for the forfeiture of, or restrictions on resale or other
disposition of, Common Stock acquired under any Stock Option,
for the acceleration of Vesting of Awards in the event of a
Change in Control of the Company, for the payment of the value
of Awards to Participants in the event of a Change in Control of
the Company, or to comply with federal and state securities
laws, or understandings or conditions as to the
Participants employment in addition to those specifically
provided for under the Plan.
17.2. Transferability. Each Award granted under the Plan
to a Participant shall not be transferable otherwise than by
will or the laws of descent and distribution or pursuant to a
qualified domestic relations order as defined in the
Code or Title I of the Employee Retirement Income Security
Act of 1974, as amended, and the rules and regulations adopted
thereunder and Stock Options and SARs shall be exercisable,
during the Participants lifetime, only by the Participant;
provided, however, that the Committee may in its sole discretion
permit the transfer of an Award to a Participants Family
Members or to one or more trusts established in whole or in part
for the benefit of one or more such Family Members In the event
of the death of a Participant, each Stock Option or SAR
theretofore granted to him or her shall be exercisable during
such period after his or her death as the Committee shall, in
its sole discretion, set forth in the Award Agreement on the
date of grant and then only by the executor or administrator of
the estate of the deceased Participant or the Person or Persons
to whom the deceased Participants rights under the Stock
Option or SAR shall pass by will or the laws of descent and
distribution.
17.3. Election to Defer Compensation Attributable to
Award. The Committee may, in its sole discretion, allow a
Participant to elect to defer the receipt of any compensation
attributable to an Award under guidelines and procedures to be
established by the Committee after taking into account the
advice of the Companys tax counsel.
17.4. Listing of Shares and Related Matters. If at any
time the Committee shall determine that the listing,
registration or qualification of the shares of Common Stock
subject to any Award on any securities exchange or under any
applicable law, or the consent or approval of any governmental
regulatory authority, is necessary or desirable as a condition
of, or in connection with, the granting of an Award or the
issuance of shares of Common Stock thereunder, such Award may
not be exercised, distributed or paid out, as the case may be,
in whole or in part, unless such listing, registration,
qualification, consent or approval shall have been effected or
obtained free of any conditions not acceptable to the Committee.
The Committee may require each Participant purchasing or
acquiring shares of Common Stock pursuant to a Stock Option or
other Award under the Plan to represent to and agree with the
Company in writing that such Participant is acquiring the shares
for investment and not with a view to the distribution thereof.
All certificates for shares of Common Stock delivered under the
Plan shall be subject to such stock-transfer orders and other
restrictions as the Committee may deem advisable under the
rules, regulations, and other requirements of the Securities and
Exchange Commission or any national securities exchange or other
market system on which the Companys securities are listed
or traded, and any applicable federal or state securities law,
and the Committee may cause a legend or legends to be put on any
such certificates to make appropriate reference to such
restrictions.
17.5. No Right, Title, or Interest in Company Assets.
Participants shall have no right, title, or interest whatsoever
in or to any investments which the Company may make to aid it in
meeting its obligations under the Plan. Nothing contained in the
Plan, and no action taken pursuant to its provisions, shall
create or be construed to create a trust of any kind, or a
fiduciary relationship between the Company and any Participant,
beneficiary, legal representative or any other Person. The Plan
is intended to constitute an unfunded plan for incentive
compensation. To the extent that any Person acquires a right to
receive payments from the Company under the Plan, such right
shall be no greater than the right of an unsecured general
creditor of the Company. All payments to be made hereunder
A-15
shall be paid from the general funds of the Company and no
special or separate fund shall be established and no segregation
of assets shall be made to assure payment of such amounts except
as expressly set forth in the Plan. The Plan is not intended to
be subject to the Employee Retirement Income Security Act of
1974, as amended.
17.6. No Right to Continued Employment or Service or to
Grants. The Participants rights, if any, to continue
to serve the Company as a director, officer, employee,
independent contractor or otherwise, shall not be enlarged or
otherwise affected by his or her designation as a Participant
under the Plan, and the Company or the applicable Subsidiary
reserves the right to terminate the employment of any Employee
or the services of any Independent Contractor or director at any
time. The adoption of the Plan shall not be deemed to give any
Employee, Nonemployee Director, Independent Contractor or any
other individual any right to be selected as a Participant or to
be granted an Award.
17.7. Awards Subject to Foreign Laws. The Committee may
grant Awards to individual Participants who are subject to the
tax laws of nations other than the United States, and such
Awards may have terms and conditions as determined by the
Committee as necessary to comply with applicable foreign laws.
The Committee may take any action, which it deems advisable to
obtain approval of such Awards by the appropriate foreign
governmental entity; provided, however, that no such Awards may
be granted pursuant to this Section 17.7 and no action may
be taken which would result in a violation of the Exchange Act
or any other applicable law.
17.8. Governing Law. The Plan, all Awards granted
hereunder, and all actions taken in connection herewith shall be
governed by and construed in accordance with the laws of the
State of Florida without reference to principles of conflict of
laws, except as superseded by applicable federal law or as
otherwise provided in any Award Agreement.
17.9. Other Benefits. No Award granted under the Plan
shall be considered compensation for purposes of computing
benefits under any retirement plan of the Company or any
Subsidiary nor affect any benefits or compensation under any
other benefit or compensation plan of the Company or any
Subsidiary now or subsequently in effect.
17.10. No Fractional Shares. No fractional shares of
Common Stock shall be issued or delivered pursuant to the Plan
or any Award. The Committee shall determine in its sole
discretion whether cash, Common Stock, Stock Options, or other
property shall be issued or paid in lieu of fractional shares or
whether such fractional shares or any rights thereto shall be
forfeited or otherwise eliminated.
17.11. Authority of the Company and Shareholders. The
existence of the Plan, the Award Agreements and the Awards
granted hereunder shall not affect or restrict in any way the
right or power of the Company or the shareholders of the Company
to make or authorize any adjustment, recapitalization,
reorganization or other change in the Companys capital
structure or its business, any merger or consolidation of the
Company, any issue of stock or of options, warrants or rights to
purchase stock or of bonds, debentures, preferred or prior
preference stocks whose rights are superior to or affect the
Common Stock or the rights thereof or which are convertible into
or exchangeable for Common Stock, or the dissolution or
liquidation of the Company, or any sale or transfer of all or
any part of its assets or business, or any other corporate act
or proceeding, whether of a similar character or otherwise.
17.12. Other Compensation Plans. The adoption of the Plan
shall not affect any other stock option, incentive or other
compensation plans in effect for the Company or any Subsidiary,
nor shall the plan preclude the Company from establishing any
other forms of incentive or other compensation for Employees and
Nonemployee Directors of the Company or any Subsidiary.
A-16